PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33627632-8 2021 The interaction between RCP and P-gp was verified endogenously and loss of RCP or mutant p53 rendered cells more sensitive to cisplatin and etoposide. Etoposide 140-149 tumor protein p53 Homo sapiens 89-92 32786121-7 2021 We further show that SENP1 depletion synergizes with DNA damage-inducing agent etoposide to induce p53 activation and the expression of p21, leading to synergistic growth inhibition of cancer cells. Etoposide 79-88 tumor protein p53 Homo sapiens 99-102 32098913-0 2020 beta-Actin facilitates etoposide-induced p53 nuclear import. Etoposide 23-32 tumor protein p53 Homo sapiens 41-44 32332775-4 2020 This interaction was enhanced by treatment with the antineoplastic drug etoposide, which suggests a role for the IL-1alpha p53 interaction in genotoxic stress. Etoposide 72-81 tumor protein p53 Homo sapiens 123-126 31940492-3 2020 In this study, we report that FBXW7, a substrate recognition component of the SKP1-CUL1-F-box (SCF) E3 ligase, interacts with and targets p53 for polyubiquitination and proteasomal degradation after exposure to ionizing radiation or etoposide. Etoposide 233-242 tumor protein p53 Homo sapiens 138-141 31940492-6 2020 Biologically, FBXW7 inactivation sensitizes cancer cells to radiation or etoposide by stabilizing p53 to induce cell-cycle arrest and apoptosis. Etoposide 73-82 tumor protein p53 Homo sapiens 98-101 31605433-4 2020 Spalax fibroblasts undergo replicative senescence (RS) and etoposide-induced senescence (EIS), evidenced by an increased activity of senescence-associated beta-galactosidase (SA-beta-Gal), growth arrest, and overexpression of p21, p16, and p53 mRNAs. Etoposide 59-68 tumor protein p53 Homo sapiens 240-243 31097220-1 2019 Etoposide-induced 2.4 kb transcript (EI24, also known as PIG8) is a p53 target gene involved in cell growth suppression and apoptosis and known to be frequently altered in human cancers. Etoposide 0-9 tumor protein p53 Homo sapiens 68-71 31528096-12 2019 Apoptosis induced by GAS2 was dependent on p53, which was increased by etoposide addition. Etoposide 71-80 tumor protein p53 Homo sapiens 43-46 31396480-5 2019 EI24 (etoposide-induced gene 2.4 kb; PIG8, p53-induced gene 8) acts as a tumor suppressor, inhibiting cell growth and inducing apoptosis in breast, cervical, and prostate cancer cells. Etoposide 6-15 tumor protein p53 Homo sapiens 43-46 30943920-13 2019 As a consequence, p53 activation by etoposide was reduced, and cell survival enhanced. Etoposide 36-45 tumor protein p53 Homo sapiens 18-21 30614034-0 2019 Signaling Crosstalk of FHIT, p53, and p38 in etoposide-induced apoptosis in MCF-7 cells. Etoposide 45-54 tumor protein p53 Homo sapiens 29-32 30614034-4 2019 The time course study showed that the expression of FHIT, p53, and p38MAPK started after 1 hour following etoposide treatment. Etoposide 106-115 tumor protein p53 Homo sapiens 58-61 30614034-8 2019 Thus, activation of p38 upon etoposide treatment leads to increase in FHIT and p53 expression. Etoposide 29-38 tumor protein p53 Homo sapiens 79-82 30614034-9 2019 In p53 knockdown MCF-7, the FHIT induction was hampered but p38 activation was induced in lower doses of etoposide. Etoposide 105-114 tumor protein p53 Homo sapiens 3-6 30614034-11 2019 Our data demonstrated that the exposure of MCF-7 cells to etoposide increases apoptosis through a mechanism involving the activation of the p38-FHIT-p53 pathway. Etoposide 58-67 tumor protein p53 Homo sapiens 149-152 30478995-0 2019 CtIP promotes G2/M arrest in etoposide-treated HCT116 cells in a p53-independent manner. Etoposide 29-38 tumor protein p53 Homo sapiens 65-68 30900772-8 2019 Blood or bone marrow samples from typical CK/MK AML patients showed defective p53 signaling upon induction by etoposide. Etoposide 110-119 tumor protein p53 Homo sapiens 78-81 30784913-0 2019 Integrated analysis of the prognostic value of TP53 dependent etoposide-induced gene 24 in non-small cell lung cancer. Etoposide 62-71 tumor protein p53 Homo sapiens 47-51 30784913-1 2019 BACKGROUND: Etoposide-induced gene 24 (EI24) is an induction target of TP53-mediated apoptosis in human cancer cells. Etoposide 12-21 tumor protein p53 Homo sapiens 71-75 30966857-4 2019 Activation of p53 by treatment with either etoposide or the small-molecule MDM2 inhibitor nutlin 3A yields strikingly similar genome-wide binding of p53 and concomitant changes to local chromatin modifications and structure. Etoposide 43-52 tumor protein p53 Homo sapiens 14-17 30966857-4 2019 Activation of p53 by treatment with either etoposide or the small-molecule MDM2 inhibitor nutlin 3A yields strikingly similar genome-wide binding of p53 and concomitant changes to local chromatin modifications and structure. Etoposide 43-52 tumor protein p53 Homo sapiens 149-152 30144069-3 2019 STK31 overexpression significantly activated PDCD5 stabilization and p53-mediated apoptosis in response to etoposide (ET). Etoposide 107-116 tumor protein p53 Homo sapiens 69-72 30144069-3 2019 STK31 overexpression significantly activated PDCD5 stabilization and p53-mediated apoptosis in response to etoposide (ET). Etoposide 118-120 tumor protein p53 Homo sapiens 69-72 29541168-0 2018 Etoposide radiosensitizes p53-defective cholangiocarcinoma cell lines independent of their G2 checkpoint efficacies. Etoposide 0-9 tumor protein p53 Homo sapiens 26-29 30520728-3 2018 RNA-Seq analysis of TFEB/TFE3 double-knockout cells exposed to etoposide reveals a profound dysregulation of the DNA damage response, including upstream regulators and downstream p53 targets. Etoposide 63-72 tumor protein p53 Homo sapiens 179-182 29397400-10 2018 We suggest that the damage to mitochondria is a major contributing factor involved in ETP-induced cardiotoxicity and the activation of the p53-mediated ferroptosis pathway by ETP is likely the critical pathway in ETP-induced cardiotoxicity. Etoposide 175-178 tumor protein p53 Homo sapiens 139-142 29397400-10 2018 We suggest that the damage to mitochondria is a major contributing factor involved in ETP-induced cardiotoxicity and the activation of the p53-mediated ferroptosis pathway by ETP is likely the critical pathway in ETP-induced cardiotoxicity. Etoposide 175-178 tumor protein p53 Homo sapiens 139-142 29471073-7 2018 Our results indicate that the underlying mechanisms whereby etoposide and ellipticine regulate CYP1A1 expression must be different and may not be linked to p53 activation alone. Etoposide 60-69 tumor protein p53 Homo sapiens 156-159 29653431-0 2018 Inhibition of NAMPT sensitizes MOLT4 leukemia cells for etoposide treatment through the SIRT2-p53 pathway. Etoposide 56-65 tumor protein p53 Homo sapiens 94-97 29653431-7 2018 After combining etoposide and FK866 treatment SIRTUIN2 was further decreased and accumulation and acetylation of the downstream target p53 was further enhanced in MOLT4 cells. Etoposide 16-25 tumor protein p53 Homo sapiens 135-138 29471073-4 2018 We found that etoposide and ellipticine induced CYP1A1 in TP53(+/+) cells but not in TP53(-/-) cells, demonstrating that the mechanism of CYP1A1 induction is p53-dependent; cisplatin had no such effect. Etoposide 14-23 tumor protein p53 Homo sapiens 58-62 29471073-4 2018 We found that etoposide and ellipticine induced CYP1A1 in TP53(+/+) cells but not in TP53(-/-) cells, demonstrating that the mechanism of CYP1A1 induction is p53-dependent; cisplatin had no such effect. Etoposide 14-23 tumor protein p53 Homo sapiens 158-161 29471073-5 2018 Co-incubation experiments with the drugs and 2.5 muM BaP showed that: (i) etoposide increased CYP1A1 expression in TP53(+/+) cells, and to a lesser extent in TP53(-/-) cells, compared to cells treated with BaP alone; (ii) ellipticine decreased CYP1A1 expression in TP53(+/+) cells in BaP co-incubations; and (iii) cisplatin did not affect BaP-mediated CYP1A1 expression. Etoposide 74-83 tumor protein p53 Homo sapiens 115-119 29309885-6 2018 Upregulation of p53 and p21 upon etoposide treatment is attenuated in HBXIP knock-down cells. Etoposide 33-42 tumor protein p53 Homo sapiens 16-19 29541168-5 2018 The present study evaluated the radiosensitization potential of etoposide in p53-defective CCA KKU-M055 and KKU-M214 cell lines. Etoposide 64-73 tumor protein p53 Homo sapiens 77-80 29541168-6 2018 Treatment with etoposide enhanced the responsiveness of two p53-defective CCA cell lines to radiation independent of G2 checkpoint function. Etoposide 15-24 tumor protein p53 Homo sapiens 60-63 29541168-8 2018 These findings indicate that etoposide could be used as a radiation sensitizer for p53-defective tumors, independent of the function of G2 checkpoint. Etoposide 29-38 tumor protein p53 Homo sapiens 83-86 29467390-14 2018 Indeed, p53 accumulates at mitochondria upon etoposide treatment and inhibition of p53 mitochondrial localization using pifithrin-micro inhibits apoptosis of COV434 cells. Etoposide 45-54 tumor protein p53 Homo sapiens 8-11 29467390-15 2018 FGF1 also decreases mitochondrial accumulation of p53 induced by etoposide. Etoposide 65-74 tumor protein p53 Homo sapiens 50-53 28195382-3 2017 This study evaluated chemical specificity of the p53 pathway response by manipulating p53 or its upstream kinases and assessing the effect on DNA damage and cellular responses to prototype chemicals: etoposide (ETP, topoisomerase II inhibitor) and methyl methane sulfonate (MMS, alkylating agent). Etoposide 211-214 tumor protein p53 Homo sapiens 49-52 29030066-0 2018 Etoposide induced NMI promotes cell apoptosis by activating the ARF-p53 signaling pathway in lung carcinoma. Etoposide 0-9 tumor protein p53 Homo sapiens 68-71 29030066-4 2018 Furthermore, etoposide treatment up-regulates the expression of NMI and ARF, enhances the interaction of NMI and ARF and promotes the p53 transcriptional activities. Etoposide 13-22 tumor protein p53 Homo sapiens 134-137 29030066-6 2018 These investigations demonstrated etoposide-induced NMI can suppress tumor proliferation and promote cell apoptosis by activating the ARF-p53 signaling pathway in lung carcinoma. Etoposide 34-43 tumor protein p53 Homo sapiens 138-141 29372665-2 2018 Chemoresistant ESC-like embryonal carcinoma PA1 cells treated with etoposide (ETO) were previously found to undergo prolonged G2 arrest with transient p53-dependent upregulation of opposing fate regulators, p21CIP1 (senescence) and OCT4A (self-renewal). Etoposide 67-76 tumor protein p53 Homo sapiens 151-154 29372665-2 2018 Chemoresistant ESC-like embryonal carcinoma PA1 cells treated with etoposide (ETO) were previously found to undergo prolonged G2 arrest with transient p53-dependent upregulation of opposing fate regulators, p21CIP1 (senescence) and OCT4A (self-renewal). Etoposide 78-81 tumor protein p53 Homo sapiens 151-154 28159923-7 2017 Of note, the combination of Vandetanib, GDC-0941 and Etoposide results in MYC-amplified and SHH-TP53-mutated cell lines in complete loss of cell viability. Etoposide 53-62 tumor protein p53 Homo sapiens 96-100 27982581-6 2017 Etoposide caused rapid accumulation of 53bp1-GFP in DNA damage foci, which was later followed by the concentration dependent nuclear accumulation of p53-GFP and subsequent induction of p21-GFP. Etoposide 0-9 tumor protein p53 Homo sapiens 149-152 27993669-6 2017 Suppression of etoposide-induced cell death correlated with a downregulation of p53 expression, which, among other functions, regulates the expression of death receptor 5, one of the activators of caspase-8. Etoposide 15-24 tumor protein p53 Homo sapiens 80-83 28195382-0 2017 Contribution of ATM and ATR kinase pathways to p53-mediated response in etoposide and methyl methanesulfonate induced DNA damage. Etoposide 72-81 tumor protein p53 Homo sapiens 47-50 28928376-5 2017 Subsequent administration of Oligo-Fucoidan to etoposide-treated cells promotes p53 accumulation, p21 expression and significant decreases in ataxia-telangiectasia-mutated (ATM), checkpoint kinase 1 (Chk1) and gamma-H2AX phosphorylation in p53+/+ cells compared with p53-/- cells. Etoposide 47-56 tumor protein p53 Homo sapiens 80-83 28928376-5 2017 Subsequent administration of Oligo-Fucoidan to etoposide-treated cells promotes p53 accumulation, p21 expression and significant decreases in ataxia-telangiectasia-mutated (ATM), checkpoint kinase 1 (Chk1) and gamma-H2AX phosphorylation in p53+/+ cells compared with p53-/- cells. Etoposide 47-56 tumor protein p53 Homo sapiens 240-243 28928376-5 2017 Subsequent administration of Oligo-Fucoidan to etoposide-treated cells promotes p53 accumulation, p21 expression and significant decreases in ataxia-telangiectasia-mutated (ATM), checkpoint kinase 1 (Chk1) and gamma-H2AX phosphorylation in p53+/+ cells compared with p53-/- cells. Etoposide 47-56 tumor protein p53 Homo sapiens 240-243 28928376-6 2017 Similarly, co-administration of Oligo-Fucoidan with etoposide inhibits ATM, Chk1 and gamma-H2AX phosphorylation, particularly in the presence of p53. Etoposide 52-61 tumor protein p53 Homo sapiens 145-148 29048426-6 2017 In both cell lines, the genotoxic drug etoposide induced a classical mitochondrial p53-dependent apoptosis. Etoposide 39-48 tumor protein p53 Homo sapiens 83-86 29137250-4 2017 This chaperone-mediated mutated p53-TAp73alpha complex induced chemoresistance to DNA damaging reagents, like Cisplatin, Doxorubicin, Etoposide or Camptothecin. Etoposide 134-143 tumor protein p53 Homo sapiens 32-35 28113103-7 2017 Analyses of caspase 3 activity, p53 acetylation and SIRT1 protein levels revealed the apoptotic nature of etoposide-evoked cell death and that fisetin and luteolin augmented the etoposide-induced acetylation of p53 and decreased SIRT1 levels. Etoposide 178-187 tumor protein p53 Homo sapiens 211-214 28051100-3 2017 Overexpression of wild-type PPEF-1, but not inactive PPEF-1D172N, efficiently suppressed CK2alpha-mediated stabilization of PDCD5 and p53-mediated apoptosis in response to etoposide (ET). Etoposide 172-181 tumor protein p53 Homo sapiens 134-137 28081228-12 2017 In contrast to cisplatin, functional p53-knock-down increased the resistance of MSC to etoposide. Etoposide 87-96 tumor protein p53 Homo sapiens 37-40 28196907-7 2017 However, upon genotoxic stress through exposure to etoposide, the deacetylase sirtuin 1 (SIRT1) deacetylated MDM2 at Lys182 and Lys185, thereby promoting self-ubiquitination and less ubiquitination and subsequent degradation of p53, thus increasing p53-dependent apoptosis. Etoposide 51-60 tumor protein p53 Homo sapiens 228-231 28196907-7 2017 However, upon genotoxic stress through exposure to etoposide, the deacetylase sirtuin 1 (SIRT1) deacetylated MDM2 at Lys182 and Lys185, thereby promoting self-ubiquitination and less ubiquitination and subsequent degradation of p53, thus increasing p53-dependent apoptosis. Etoposide 51-60 tumor protein p53 Homo sapiens 249-252 27545311-7 2016 Among these genes, 2 genes (PRODH and DAO) were found to be directly regulated by p53, and ectopic expression of 4 genes (PRODH, DAO, EPN3, and GPR172B) affected senescence phenotypes induced by etoposide treatment. Etoposide 195-204 tumor protein p53 Homo sapiens 82-85 27514406-8 2016 IMPLICATIONS: This study provides a solid rationale for the stratification of lung adenocarcinoma patients according to the functional ERCC1- and mutational TP53 status, where functionally ERCC1-incompetent patients could benefit from sequential cisplatin and etoposide chemotherapy. Etoposide 260-269 tumor protein p53 Homo sapiens 157-161 26259609-0 2015 Etoposide Induces Necrosis Through p53-Mediated Antiapoptosis in Human Kidney Proximal Tubule Cells. Etoposide 0-9 tumor protein p53 Homo sapiens 35-38 26986476-8 2016 The results showed that knockdown of PTEN strongly antagonized ATM activation in response to etoposide treatment, and thereby reduced the phosphorylation level of ATM substrates, including H2AX, P53 and Chk2. Etoposide 93-102 tumor protein p53 Homo sapiens 195-198 26646449-12 2016 Furthermore, SIRT1 knockdown resulted in cell cycle arrest, induction of apoptosis and reduction of K562 cell proliferation accompanied by enhanced p53 and FOXO1 acetylation in K562 cells after etoposide treatment. Etoposide 194-203 tumor protein p53 Homo sapiens 148-151 27069137-8 2016 Moreover, depletion of PANDA prevented accumulation of p53 protein, as a result of DNA damage, induced by the genotoxic agent etoposide. Etoposide 126-135 tumor protein p53 Homo sapiens 55-58 26973857-2 2016 The tumor suppressor, p53 is central for apoptotic response to multiple DNA damaging agents used to treat aggressive B-cell lymphomas, including etoposide. Etoposide 145-154 tumor protein p53 Homo sapiens 22-25 26973857-5 2016 Using B-cell lymphoma cell lines resistant to etoposide induced cell death; we show that p53 is dramatically down regulated and MDMX, a negative regulator of p53, is significantly up regulated. Etoposide 46-55 tumor protein p53 Homo sapiens 89-92 26625199-4 2016 In HCT116 p53+/+ cells treated with the DNA-damaging agent, etoposide, HBZ reduced p53-mediated activation of p21/CDKN1A and GADD45A expression, which was associated with a delay in G2 phase-arrest. Etoposide 60-69 tumor protein p53 Homo sapiens 10-13 26625199-4 2016 In HCT116 p53+/+ cells treated with the DNA-damaging agent, etoposide, HBZ reduced p53-mediated activation of p21/CDKN1A and GADD45A expression, which was associated with a delay in G2 phase-arrest. Etoposide 60-69 tumor protein p53 Homo sapiens 83-86 26259609-7 2015 Thus, our study demonstrated that p53 protects against apoptosis, and leads to etoposide-induced necrosis. Etoposide 79-88 tumor protein p53 Homo sapiens 34-37 26070487-3 2015 Through an unbiased genome-wide ChIP-seq analysis, we have found that 5-lipoxygenase (ALOX5, 5-LO) which is a key enzyme of leukotriene (LT) biosynthesis, is a direct target gene of p53 and its expression is induced by genotoxic stress via actinomycin D (Act.D) or etoposide (Eto) treatment. Etoposide 265-274 tumor protein p53 Homo sapiens 182-185 26070487-3 2015 Through an unbiased genome-wide ChIP-seq analysis, we have found that 5-lipoxygenase (ALOX5, 5-LO) which is a key enzyme of leukotriene (LT) biosynthesis, is a direct target gene of p53 and its expression is induced by genotoxic stress via actinomycin D (Act.D) or etoposide (Eto) treatment. Etoposide 276-279 tumor protein p53 Homo sapiens 182-185 25954860-5 2015 It has been demonstrated that most chemotherapy drugs exert their anti-cancer effects via p53-mediated apoptosis, and in accordance, with this, the present study showed that treatment with etoposide significantly increased p53 levels. Etoposide 189-198 tumor protein p53 Homo sapiens 90-93 25444898-8 2015 However, DNAJB1 knockdown in A549 cells increased the etoposide-induced activation of the p53-mediated apoptosis pathway and repressed cancer cell growth. Etoposide 54-63 tumor protein p53 Homo sapiens 90-93 25954860-5 2015 It has been demonstrated that most chemotherapy drugs exert their anti-cancer effects via p53-mediated apoptosis, and in accordance, with this, the present study showed that treatment with etoposide significantly increased p53 levels. Etoposide 189-198 tumor protein p53 Homo sapiens 223-226 25954860-7 2015 This was further verified in CCRCC tissue specimens from patients The results of the present study suggested that loss of PTEN, which deactivated Akt/HDM2 signaling followed by degradation of p53, may contribute to the development of etoposide resistance in CCRCC. Etoposide 234-243 tumor protein p53 Homo sapiens 192-195 26158294-9 2015 Treatment with nutlin-3a or etoposide induced CST5 in a p53-dependent manner. Etoposide 28-37 tumor protein p53 Homo sapiens 56-59 25568206-9 2015 However, expression of these genes did not attain the levels observed when p53 was activated in response to etoposide treatment and remained lower than those measured in mock-infected cells. Etoposide 108-117 tumor protein p53 Homo sapiens 75-78 25964101-7 2015 In ovarian cancer cells, where >90% have inactivated p53, Nutlin combined with the genotoxic agents, cisplatin or etoposide, had a cooperative lethal effect resulting in increased DNA damage and apoptosis. Etoposide 117-126 tumor protein p53 Homo sapiens 56-59 26077467-4 2015 Genetic deletion of PDCD5 abrogates etoposide (ET)-induced p53 stabilization and HDAC3 cleavage, indicating an essential role of PDCD5 in p53 activation. Etoposide 36-45 tumor protein p53 Homo sapiens 59-62 26077467-4 2015 Genetic deletion of PDCD5 abrogates etoposide (ET)-induced p53 stabilization and HDAC3 cleavage, indicating an essential role of PDCD5 in p53 activation. Etoposide 36-45 tumor protein p53 Homo sapiens 138-141 26077467-4 2015 Genetic deletion of PDCD5 abrogates etoposide (ET)-induced p53 stabilization and HDAC3 cleavage, indicating an essential role of PDCD5 in p53 activation. Etoposide 47-49 tumor protein p53 Homo sapiens 59-62 26077467-4 2015 Genetic deletion of PDCD5 abrogates etoposide (ET)-induced p53 stabilization and HDAC3 cleavage, indicating an essential role of PDCD5 in p53 activation. Etoposide 47-49 tumor protein p53 Homo sapiens 138-141 25088203-7 2015 Furthermore, the phosphorylation of ATM targets, including gammaH2AX, threonine 68 (T68) on CHK2 (CHK2 pT68) and serine 15 (S15) on p53 were decreased in overexpression and increased in knockdown BMI1 cells in response to ETOP. Etoposide 222-226 tumor protein p53 Homo sapiens 132-135 25821946-9 2015 Furthermore, phosphorylation of ATM targets, including gammaH2AX and serine 15 (S15) on p53, were increased in Rap1 silencing cells in response to etoposide. Etoposide 147-156 tumor protein p53 Homo sapiens 88-91 25750273-0 2015 The effect of silibinin in enhancing toxicity of temozolomide and etoposide in p53 and PTEN-mutated resistant glioma cell lines. Etoposide 66-75 tumor protein p53 Homo sapiens 79-82 25866679-4 2015 As expected, etoposide-treated wild-type p53-containing cell lines, LFS 2852 and control Jurkat, showed a greater rate of caspase- and annexin V-induced apoptotic cell death compared to the p53-mutant LFS 2673 cell line although mitochondrial and nuclear assays could not detect apoptosis in these organelles. Etoposide 13-22 tumor protein p53 Homo sapiens 41-44 26102294-3 2015 Previously, we showed that following etoposide (ETO) treatment embryonal carcinoma PA-1 cells undergo a p53-dependent upregulation of OCT4A and p21Cip1 (governing self-renewal and regulating cell cycle inhibition and senescence, respectively). Etoposide 37-46 tumor protein p53 Homo sapiens 104-107 26102294-3 2015 Previously, we showed that following etoposide (ETO) treatment embryonal carcinoma PA-1 cells undergo a p53-dependent upregulation of OCT4A and p21Cip1 (governing self-renewal and regulating cell cycle inhibition and senescence, respectively). Etoposide 48-51 tumor protein p53 Homo sapiens 104-107 25866679-4 2015 As expected, etoposide-treated wild-type p53-containing cell lines, LFS 2852 and control Jurkat, showed a greater rate of caspase- and annexin V-induced apoptotic cell death compared to the p53-mutant LFS 2673 cell line although mitochondrial and nuclear assays could not detect apoptosis in these organelles. Etoposide 13-22 tumor protein p53 Homo sapiens 190-193 25490093-0 2014 p53-dependent activation of microRNA-34a in response to etoposide-induced DNA damage in osteosarcoma cell lines not impaired by dominant negative p53 expression. Etoposide 56-65 tumor protein p53 Homo sapiens 0-3 25490093-3 2014 In this study we evaluated the cascade of events determined by etoposide-induced DNA damage in OS cell lines with different p53 status focusing on methylation status and expression of miR-34a that modulate tumor cell growth and cell cycle progression. Etoposide 63-72 tumor protein p53 Homo sapiens 124-127 25490093-6 2014 Consistently, in p53siRNA transfected U2-OS cells we observed loss of miR-34a induction after etoposide exposure associated with a partial gain of gene methylation and cell cycle progress towards G2/M phase. Etoposide 94-103 tumor protein p53 Homo sapiens 17-20 25490093-8 2014 In conclusion, cell response to etoposide-induced DNA damage was not compromised in cells with dominant-negative p53 expression. Etoposide 32-41 tumor protein p53 Homo sapiens 113-116 25490093-4 2014 Wild-type p53 U2-OS cells and U2-OS cells expressing dominant-negative form of p53 (U2- OS175) were more sensitive to etoposide than p53-deficient MG63 and Saos-2 cells, showing increased levels of unmethylated miR-34a, reduced expression of CDK4 and cell cycle arrest in G1 phase. Etoposide 118-127 tumor protein p53 Homo sapiens 10-13 25490093-4 2014 Wild-type p53 U2-OS cells and U2-OS cells expressing dominant-negative form of p53 (U2- OS175) were more sensitive to etoposide than p53-deficient MG63 and Saos-2 cells, showing increased levels of unmethylated miR-34a, reduced expression of CDK4 and cell cycle arrest in G1 phase. Etoposide 118-127 tumor protein p53 Homo sapiens 79-82 25490093-4 2014 Wild-type p53 U2-OS cells and U2-OS cells expressing dominant-negative form of p53 (U2- OS175) were more sensitive to etoposide than p53-deficient MG63 and Saos-2 cells, showing increased levels of unmethylated miR-34a, reduced expression of CDK4 and cell cycle arrest in G1 phase. Etoposide 118-127 tumor protein p53 Homo sapiens 79-82 24786831-5 2014 PELP1-depleted p53 (wild-type) breast cancer cells were less sensitive to various genotoxic agents including etoposide, camptothecin or gamma-radiation. Etoposide 109-118 tumor protein p53 Homo sapiens 15-18 25250818-5 2014 Treatment with etoposide, increased miR-34a levels in a p53-dependent fashion and the level of miR-34a transcription was correlated with the cell sensitivity to etoposide. Etoposide 15-24 tumor protein p53 Homo sapiens 56-59 23318437-10 2014 The regulation on p53 and MDM2 stability by RNF2 was also observed during the etoposide-induced DNA damage response. Etoposide 78-87 tumor protein p53 Homo sapiens 18-21 24486906-6 2014 Bimodal p53 dynamics was largely influenced by cellular MDM2 and elevated p53/MDM2 ratios with increasing etoposide favor mono-ubiquitination. Etoposide 106-115 tumor protein p53 Homo sapiens 8-11 24486906-6 2014 Bimodal p53 dynamics was largely influenced by cellular MDM2 and elevated p53/MDM2 ratios with increasing etoposide favor mono-ubiquitination. Etoposide 106-115 tumor protein p53 Homo sapiens 74-77 24743655-5 2014 Transcriptome profiling, using RNAseq, in response to the DNA-damaging agent etoposide revealed a large number of Tp53-regulated transcripts, but also a subset of transcripts that were TP53Pro72Arg allele specific. Etoposide 77-86 tumor protein p53 Homo sapiens 114-118 24743655-5 2014 Transcriptome profiling, using RNAseq, in response to the DNA-damaging agent etoposide revealed a large number of Tp53-regulated transcripts, but also a subset of transcripts that were TP53Pro72Arg allele specific. Etoposide 77-86 tumor protein p53 Homo sapiens 185-189 24626184-8 2014 However, its recruitment is stimulated by etoposide in cells lacking p53, suggesting that p53 can oppose association of p68 with the PLK1 promoter. Etoposide 42-51 tumor protein p53 Homo sapiens 90-93 24056736-3 2014 We exploited this system to examine select post-translational modifications (PTMs) present on a transcriptionally inert population of endogenous human p53, as well as on p53 activated in response to etoposide treatment of normal human fibroblasts. Etoposide 199-208 tumor protein p53 Homo sapiens 170-173 24056736-7 2014 Despite the differences in activity, including greater in vitro sequence-specific DNA binding activity exhibited by p53 isolated from etoposide-treated cells, few differences were observed in the location, nature, or relative frequencies of PTMs on the two populations of human p53. Etoposide 134-143 tumor protein p53 Homo sapiens 116-119 22469985-6 2013 Moreover, viral reactivation compromised p53-dependent apoptosis in PEL cells treated with genotoxic anti-cancer agents doxorubicin and etoposide. Etoposide 136-145 tumor protein p53 Homo sapiens 41-44 24732641-0 2014 MDM2 rs2279744 and TP53 rs1042522 polymorphisms associated with etoposide- and cisplatin-induced grade III/IV neutropenia in Chinese extensive-stage small-cell lung cancer patients. Etoposide 64-73 tumor protein p53 Homo sapiens 19-23 24055188-7 2013 P53 expression was up-regulated by resveratrol and etoposide and pre-incubation of both cells with resveratrol increased levels of etoposide-induced p53 expression. Etoposide 51-60 tumor protein p53 Homo sapiens 0-3 24055188-7 2013 P53 expression was up-regulated by resveratrol and etoposide and pre-incubation of both cells with resveratrol increased levels of etoposide-induced p53 expression. Etoposide 131-140 tumor protein p53 Homo sapiens 0-3 24055188-7 2013 P53 expression was up-regulated by resveratrol and etoposide and pre-incubation of both cells with resveratrol increased levels of etoposide-induced p53 expression. Etoposide 131-140 tumor protein p53 Homo sapiens 149-152 24055188-9 2013 It seems that resveratrol exerts differential synergistic effect with etoposide on proliferation of cancer cells from different origin which is mainly accompanied by p53 activation. Etoposide 70-79 tumor protein p53 Homo sapiens 166-169 23954287-4 2013 Moreover, we showed that etoposide, a DNA damaging agent, activates p53 transcription through the E2F1 pathway. Etoposide 25-34 tumor protein p53 Homo sapiens 68-71 23161404-3 2013 In this study, we demonstrated that lithium and SB216763, which are pharmacological inhibitors of GSK3, attenuated p53 accumulation and caspase-3 activation, as shown by PARP cleavage induced by the DNA-damaging agents doxorubicin, etoposide and camptothecin. Etoposide 232-241 tumor protein p53 Homo sapiens 115-118 23161404-7 2013 GSK3 inhibition also reduced the phosphorylation of wild-type p53 at serine 33, which is induced by doxorubicin, etoposide and camptothecin in the mitochondria. Etoposide 113-122 tumor protein p53 Homo sapiens 62-65 23161404-8 2013 Moreover, inhibition of GSK3 reduced etoposide-induced association of p53 with Bcl2 and Bax oligomerization. Etoposide 37-46 tumor protein p53 Homo sapiens 70-73 23835407-0 2013 miR-375 targets the p53 gene to regulate cellular response to ionizing radiation and etoposide in gastric cancer cells. Etoposide 85-94 tumor protein p53 Homo sapiens 20-23 23835407-10 2013 These results demonstrate that miR-375 targets p53 to regulate the response to ionizing radiation and etoposide treatment. Etoposide 102-111 tumor protein p53 Homo sapiens 47-50 23690541-7 2013 Unexpectedly, induction of p53 by etoposide was not inhibited by cordycepin, whereas (1) expression of Sp1 (required for the induction of p21(WAF1/CIP1) and activation of p16(INK4a) by genotoxic stress) was attenuated by cordycepin, (2) DNA binding activity of Sp1 was also inhibited, and (3) selective inhibition of Sp1 reproduced the suppressive effect of cordycepin on senescence. Etoposide 34-43 tumor protein p53 Homo sapiens 27-30 23474493-5 2013 CBX8 cooperated with SIRT1 for suppressing p53 acetylation induced by Sirtinol and etoposide/TSA. Etoposide 83-92 tumor protein p53 Homo sapiens 43-46 23382381-4 2013 Cellular responses to DNA damage induced by etoposide or doxorubicin include down-regulation of endogenous supervillin coincident with increases in p53. Etoposide 44-53 tumor protein p53 Homo sapiens 148-151 23287532-3 2013 To investigate these phenomena and their relationship to pluripotency and senescence, we examined the response of the TP53-competent embryonal carcinoma (EC) cell line PA-1 to etoposide-induced DNA damage. Etoposide 176-185 tumor protein p53 Homo sapiens 118-122 22763759-6 2012 However, the growth-inhibitory activity of vincristine, doxorubicin, carboplatin, etoposide, and temozolomide was significantly impaired by silencing of TP53. Etoposide 82-91 tumor protein p53 Homo sapiens 153-157 23150668-9 2013 Furthermore, we showed that PHF1 regulates cell growth arrest and etoposide-induced apoptosis in a p53-dependent manner. Etoposide 66-75 tumor protein p53 Homo sapiens 99-102 23054612-6 2013 Importantly, when p53 was activated following the administration of either of three different anticancer chemotherapeutic agents (cisplatin, etoposide or doxorubicin), it was able to induce CYP3A genes, which are the main factors in systemic clearance of these agents. Etoposide 141-150 tumor protein p53 Homo sapiens 18-21 23058634-3 2012 Indeed, we showed that etoposide could influence transcription and was able to activate DDR in resting human T cells by inducing phosphorylation of ATM and its substrates, H2AX and p53. Etoposide 23-32 tumor protein p53 Homo sapiens 181-184 22948151-6 2012 Induction of p53 can be achieved by several means, such as UV radiation and treatment with anti-cancer agents (including doxorubicin, etoposide, roscovitine, flavopiridol, and nutlin-3). Etoposide 134-143 tumor protein p53 Homo sapiens 13-16 22830357-6 2012 In accordance with this hypothesis, etoposide or nutlin-3 treatment or a small interfering RNA (siRNA) against BCL6 (B-cell lymphoma 6) inhibited the proliferation of DoHH2 cells by up-regulating p53 without affecting either miR-34a or c-MYC levels. Etoposide 36-45 tumor protein p53 Homo sapiens 196-199 22739265-6 2012 In addition, etoposide induced p53 phosphorylation and H2AX foci formation in proliferating SH-SY5Y cells but failed to do so in differentiated SH-SY5Y cells. Etoposide 13-22 tumor protein p53 Homo sapiens 31-34 22508727-0 2012 Mutant p53 cooperates with ETS2 to promote etoposide resistance. Etoposide 43-52 tumor protein p53 Homo sapiens 7-10 22904680-5 2012 In vitro, p53-72P was less effective than p53-72R in inducing apoptosis and inhibiting survival of p53-null LAN-1 cells treated with etoposide, topotecan, or ionizing radiation but not taxol. Etoposide 133-142 tumor protein p53 Homo sapiens 10-13 22511763-8 2012 Etoposide treatment also resulted in activation of the upstream promoter as well as nuclear accumulation of TLP and p53. Etoposide 0-9 tumor protein p53 Homo sapiens 116-119 22904680-6 2012 By contrast, p53-72P was more effective in promoting p21-dependent accelerated senescence, alone or in the presence of etoposide. Etoposide 119-128 tumor protein p53 Homo sapiens 13-16 22200537-0 2012 Liposomal formulations of Etoposide and Docetaxel for p53 mediated enhanced cytotoxicity in lung cancer cell lines. Etoposide 26-35 tumor protein p53 Homo sapiens 54-57 22200537-1 2012 The objective of present investigation was to develop and assess comparative enhancement in cytotoxicity of liposomal Etoposide and Docetaxel in non-small cell lung cancer cell lines after pre-treatment and co-administration of p53 tumor suppressor gene and to assess direct lung targeting of optimized formulations by dry powder inhaler technology. Etoposide 118-127 tumor protein p53 Homo sapiens 228-231 21801448-0 2011 Essential role of caspase-8 in p53/p73-dependent apoptosis induced by etoposide in head and neck carcinoma cells. Etoposide 70-79 tumor protein p53 Homo sapiens 31-34 23272236-4 2012 Etoposide-treated cells exhibited a senescent phenotype characterized by senile morphology, positive staining for senescence-associated beta-galactosidase, growth arrest and induction of p53 and p21(WAF1/CIP1). Etoposide 0-9 tumor protein p53 Homo sapiens 187-190 21801448-11 2011 Our data suggest the importance of caspase-8-mediated positive feedback amplification in the p53/p73-dependent apoptosis induced by etoposide in HNSCC cells. Etoposide 132-141 tumor protein p53 Homo sapiens 93-96 21552291-7 2011 By contrast, p53(-/-) cells are expectedly resistant to cell death upon exposure to DNA-damaging agents such as cisplatin (CDDP) and etoposide. Etoposide 133-142 tumor protein p53 Homo sapiens 13-16 21903579-4 2011 A focused real-time quantitative reverse transcription PCR array of known p53-regulated genes identified p21(WAF1) (CDKN1A) as the highest ranked gene to be differentially expressed between B-cell precursor (BCP)-ALL and T-ALL xenografts following exposure to the DNA-damaging drug etoposide. Etoposide 282-291 tumor protein p53 Homo sapiens 74-77 21441950-8 2011 Instead, a natural antisense transcript of TP53, WRAP53, was strongly augmented by idarubicin and etoposide, but only less so by the other anthracyclines under study. Etoposide 98-107 tumor protein p53 Homo sapiens 43-47 21801448-4 2011 RESULTS: We show that p53/p73-dependent caspase-8 activation is required for sensitizing etoposide-induced apoptosis by utilizing HOC313 cells carrying a temperature-sensitive p53G285K mutant. Etoposide 89-98 tumor protein p53 Homo sapiens 22-25 21801448-7 2011 In etoposide-sensitive Ca9-22 cells carrying a temperature-insensitive mutant p53, siRNA-based p73 knockdown blocked etoposide-induced apoptosis and procaspase-8 cleavage. Etoposide 117-126 tumor protein p53 Homo sapiens 78-81 21801448-9 2011 Finally, the caspase-9 inhibitor Ac-LEHD-CHO or caspase-9 siRNA blocked etoposide-induced caspase-8 activation, Bid cleavage, and apoptosis in both cell lines, indicating that p53/p73-dependent caspase-8 activation lies downstream of mitochondria. Etoposide 72-81 tumor protein p53 Homo sapiens 176-179 21801448-10 2011 CONCLUSIONS: we conclude that p53 and p73 can act as upstream regulators of caspase-8, and that caspase-8 is an essential mediator of the p53/p73-dependent apoptosis induced by etoposide in HNSCC cells. Etoposide 177-186 tumor protein p53 Homo sapiens 30-33 21801448-10 2011 CONCLUSIONS: we conclude that p53 and p73 can act as upstream regulators of caspase-8, and that caspase-8 is an essential mediator of the p53/p73-dependent apoptosis induced by etoposide in HNSCC cells. Etoposide 177-186 tumor protein p53 Homo sapiens 138-141 21554433-8 2011 Both Odora cells (an olfactive cell line) and OM cells treated with etoposide, a p53 activity inducer, exhibited mitochondrial-dependent apoptosis that was inhibited by the pan-caspase inhibitor zVAD-fmk. Etoposide 68-77 tumor protein p53 Homo sapiens 81-84 21468663-4 2011 In this study, we showed that etoposide treatment activated caspase-8 and caspase-3, leading to cleavages of p53, Bid and PARP, which subsequently induced apoptosis. Etoposide 30-39 tumor protein p53 Homo sapiens 109-112 21468663-5 2011 Furthermore, p53 and Bid were accumulated in cytoplasm following etoposide treatment. Etoposide 65-74 tumor protein p53 Homo sapiens 13-16 21565980-7 2011 DNA-damaging chemotherapeutics, such as etoposide, activate a functional loop linking SIRT1 and p53 through the induction of miR-34a. Etoposide 40-49 tumor protein p53 Homo sapiens 96-99 21468663-9 2011 Moreover, the pretreatment with trichostatin A (TSA, a histone deacetylase inhibitor) or TSA in combination with etoposide significantly sensitized HCC cells to apoptosis by inhibiting ERK phosphorylation, reactivating caspases and PARP, and inducing translocation of p53 and Bid to cytoplasm. Etoposide 113-122 tumor protein p53 Homo sapiens 268-271 20840860-6 2010 Downregulation of p53 target genes BAX and/or GADD45 alpha led to decreased in PPP1R13L activation after adriamycin and/or etoposide treatments. Etoposide 123-132 tumor protein p53 Homo sapiens 18-21 20931131-3 2011 This report describes a series of high-throughput LanthaScreen time-resolved Forster resonance energy transfer (TR-FRET) immunoassays for detection of intracellular p53 phosphorylation of Ser15 and acetylation of Lys382 upon treatment with DNA damage agents, such as etoposide. Etoposide 268-277 tumor protein p53 Homo sapiens 166-169 20931131-5 2011 First, BacMam-mediated overexpression of SIRT1 resulted in dose-dependent deacetylation of GFP-p53 following etoposide treatment of U-2 OS cells, confirming that GFP-p53 serves as a SIRT1 substrate in this assay format. Etoposide 109-118 tumor protein p53 Homo sapiens 95-98 21274505-6 2011 Furthermore, activation of p53 and AMPK was detected in etoposide-treated cells and inhibition of AMPK triggered apoptosis through suppression of autophagy. Etoposide 56-65 tumor protein p53 Homo sapiens 27-30 21394211-3 2011 Here, we have analyzed the p53-regulated pathways induced by Actinomycin D and Etoposide treatment resulting in more growth arrested versus apoptotic cells respectively. Etoposide 79-88 tumor protein p53 Homo sapiens 27-30 21386980-6 2011 Induction of DNA damage by UV, IR, etoposide and doxorubicin stabilizes p53 and induces DRAM expression, followed by VRK1 downregulation and a reduction in p53 Thr18 phosphorylation. Etoposide 35-44 tumor protein p53 Homo sapiens 72-75 21386980-6 2011 Induction of DNA damage by UV, IR, etoposide and doxorubicin stabilizes p53 and induces DRAM expression, followed by VRK1 downregulation and a reduction in p53 Thr18 phosphorylation. Etoposide 35-44 tumor protein p53 Homo sapiens 156-159 20931131-5 2011 First, BacMam-mediated overexpression of SIRT1 resulted in dose-dependent deacetylation of GFP-p53 following etoposide treatment of U-2 OS cells, confirming that GFP-p53 serves as a SIRT1 substrate in this assay format. Etoposide 109-118 tumor protein p53 Homo sapiens 166-169 20655369-4 2010 Our results revealed a significant P53-induction by actinomycin D, methyl methanesulfonate and etoposide. Etoposide 95-104 tumor protein p53 Homo sapiens 35-38 21080495-10 2010 We used this method to study differences in protein localization in HCT116 cells either with or without p53, and studied the differences in cellular response to DNA damage following treatment of HCT116 cells with etoposide in both p53 wild-type and null genetic backgrounds. Etoposide 213-222 tumor protein p53 Homo sapiens 231-234 20226587-3 2010 Co-treatment of etoposide and KG-135 markedly elevated the expression and phosphorylation at the serine 15 residue of p53 as well as the cellular levels of Bax and p21(Waf1/Cip1). Etoposide 16-25 tumor protein p53 Homo sapiens 118-121 20622893-7 2010 BRCA1-IRIS abrogation of the homeostatic balance maintained by the p38MAPK-p53-WIP1 pathway suppressed cell death induced by a lethal dose of short-wavelength UV light, and high dosage of etoposide or H(2)O(2), and allowed cells to survive and proliferate post geno-/cell-toxic stresses. Etoposide 188-197 tumor protein p53 Homo sapiens 75-78 20226587-6 2010 Our results indicate that etoposide-induced apoptosis in HeLa cells can be potentiated in the presence of KG-135 through a mechanism that involves the stabilization of p53 and the stimulation of Bax- and p21-mediated apoptotic signaling pathways. Etoposide 26-35 tumor protein p53 Homo sapiens 168-171 20053762-7 2010 This compound abrogates an etoposide-induced G(2) arrest with an IC(50) of 55 nmol/L in HT29 cells, and significantly enhances the cell killing of gemcitabine and SN38 by 3.0- to 29-fold in several colon tumor lines in vitro and in a p53-dependent fashion. Etoposide 27-36 tumor protein p53 Homo sapiens 234-237 20299546-2 2010 In this study, we show that TCDD treatment counteracts the p53 activation (phosphorylation and acetylation) elicited by a genotoxic compound, etoposide, in the human hepatocarcinoma cell line HepG2 and we delineated the mechanisms of this interaction. Etoposide 142-151 tumor protein p53 Homo sapiens 59-62 21364648-0 2010 p53-mediated delayed NF-kappaB activity enhances etoposide-induced cell death in medulloblastoma. Etoposide 49-58 tumor protein p53 Homo sapiens 0-3 21364648-2 2010 Using several MB cell lines, we have demonstrated that the chemotherapeutic drug etoposide induces a p53- and caspase-dependent cell death. Etoposide 81-90 tumor protein p53 Homo sapiens 101-104 19629643-5 2010 Here, we show that four of seven types of DNA damage signals we examined (induction by etoposide, doxorubicin, camptothecin and cisplatin treatment) resulted in significant Apak phosphorylation and dissociation of Apak from p53, releasing the inhibition of p53 transcriptional activity. Etoposide 87-96 tumor protein p53 Homo sapiens 224-227 19629643-5 2010 Here, we show that four of seven types of DNA damage signals we examined (induction by etoposide, doxorubicin, camptothecin and cisplatin treatment) resulted in significant Apak phosphorylation and dissociation of Apak from p53, releasing the inhibition of p53 transcriptional activity. Etoposide 87-96 tumor protein p53 Homo sapiens 257-260 20845286-7 2010 BRCA1-IRIS abrogation of the homeostatic balance maintained by p38MAPK-p53-WIP1 pathway suppressed cell death induced by a lethal dose of UVC, high dosages of etoposide or H2O2, and allowed cells to survive and proliferate post geno-/cell-toxic stresses. Etoposide 159-168 tumor protein p53 Homo sapiens 71-74 20075077-4 2010 Treatment with the genotoxic agents, doxorubicin or etoposide, induced Foxp3 expression in p53-positive carcinoma cells, but not in cells lacking p53 function. Etoposide 52-61 tumor protein p53 Homo sapiens 91-94 19858204-6 2009 Additionally, cells treated with anti-cancer drug etoposide underwent apoptosis in association with the transcriptional enhancement of TAp63 in a p53-independent manner, and the knockdown of the endogenous TLP reduced etoposide-induced apoptosis through repression of TAp63 expression. Etoposide 50-59 tumor protein p53 Homo sapiens 146-149 19794957-0 2009 Hypoxia-induced decrease in p53 protein level and increase in c-jun DNA binding activity results in cancer cell resistance to etoposide. Etoposide 126-135 tumor protein p53 Homo sapiens 28-31 20025574-0 2009 Association of p53 with Bid induces cell death in response to etoposide treatment in hepatocellular carcinoma. Etoposide 62-71 tumor protein p53 Homo sapiens 15-18 20025574-6 2009 Here, we showed that etoposide-induced DNA damage could significantly induce p53 and Bid nuclear export. Etoposide 21-30 tumor protein p53 Homo sapiens 77-80 20025574-7 2009 When cells were stimulated by etoposide, p53 could, through the association with Bid, cause translocation of Bid from the nucleus to the cytoplasm and on to its ultimate location in the mitochondria. Etoposide 30-39 tumor protein p53 Homo sapiens 41-44 20025574-8 2009 p53 was physically associated with Bid, and both p53 and Bid cooperatively promoted cell death induced by etoposide. Etoposide 106-115 tumor protein p53 Homo sapiens 0-3 20025574-8 2009 p53 was physically associated with Bid, and both p53 and Bid cooperatively promoted cell death induced by etoposide. Etoposide 106-115 tumor protein p53 Homo sapiens 49-52 20025574-10 2009 These findings reveal a novel mechanism by which p53 is associated with Bid in the nucleus to facilitate exportation of Bid to the mitochondria and induce apoptosis in response to etoposide-induced DNA damage in HCC. Etoposide 180-189 tumor protein p53 Homo sapiens 49-52 19751709-8 2009 This effect correlated with lowered basal levels of p53, as well as with an attenuated p53 response induced by etoposide and leptomycin B. Etoposide 111-120 tumor protein p53 Homo sapiens 87-90 19794957-4 2009 Whereas the profile of c-Myc and NF-kappaB activity did not fit the effect of hypoxia on caspase 3 activity, hypoxia decreased basal p53 abundance and DNA binding activity as well as p53 etoposide-induced activation. Etoposide 187-196 tumor protein p53 Homo sapiens 183-186 19794957-5 2009 Short interfering RNA (siRNA) silencing evidenced that p53 was required for etoposide-induced apoptosis under normoxia. Etoposide 76-85 tumor protein p53 Homo sapiens 55-58 19794957-12 2009 These data evidenced that hypoxia decreased the responsiveness of HepG2 cells to etoposide at least by two independent pathways involving p53 inhibition and c-jun activation. Etoposide 81-90 tumor protein p53 Homo sapiens 138-141 19488905-2 2009 Etoposide initiated DNA-damage signaling via ATM kinase and activated p53 pathway and caspase-2. Etoposide 0-9 tumor protein p53 Homo sapiens 70-73 19261878-4 2009 Despite promoting nuclear p53 accumulation, Class I/II HDAC inhibitors (HDACIs) protected neurons from p53-dependent cell death induced by camptothecin, etoposide, heterologous p53 expression or the MDM2 inhibitor, nutlin-3a. Etoposide 153-162 tumor protein p53 Homo sapiens 103-106 19637078-6 2009 Other genes regulated by the transformation-related protein 53 (Trp53/p53) such as Bcl2-associated X protein (Bax) or etoposide-induced-2.4 (Ei24/PIG8) were not upregulated. Etoposide 118-127 tumor protein p53 Homo sapiens 29-62 19261878-4 2009 Despite promoting nuclear p53 accumulation, Class I/II HDAC inhibitors (HDACIs) protected neurons from p53-dependent cell death induced by camptothecin, etoposide, heterologous p53 expression or the MDM2 inhibitor, nutlin-3a. Etoposide 153-162 tumor protein p53 Homo sapiens 103-106 18557930-7 2008 On the other hand, p53 activator, etoposide, decreased the MMP-1 expression in both normal and p53-overexpressed cells. Etoposide 34-43 tumor protein p53 Homo sapiens 19-22 19305157-0 2009 Diversity of DNA damage response of astrocytes and glioblastoma cell lines with various p53 status to treatment with etoposide and temozolomide. Etoposide 117-126 tumor protein p53 Homo sapiens 88-91 18557930-7 2008 On the other hand, p53 activator, etoposide, decreased the MMP-1 expression in both normal and p53-overexpressed cells. Etoposide 34-43 tumor protein p53 Homo sapiens 95-98 18200038-0 2008 A novel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLL. Etoposide 31-40 tumor protein p53 Homo sapiens 98-102 18594537-0 2008 Attenuated p53 activation in tumour-associated stromal cells accompanies decreased sensitivity to etoposide and vincristine. Etoposide 98-107 tumor protein p53 Homo sapiens 11-14 18206427-8 2008 Etoposide-induced phosphorylation of p53 relied mainly on RIP, whereas activation of Chk1, Chk2 depended largely on TIP. Etoposide 0-9 tumor protein p53 Homo sapiens 37-40 18559532-4 2008 In this study, we show that Tax sensitizes p53-mutant cells to a broad range of DNA-damaging agents, including mitomycin C, a bifunctional alkylator, etoposide, a topoisomerase II drug, and UV light, but not ionizing radiation, a double-strand break agent, or vinblastine, a tubulin poison. Etoposide 150-159 tumor protein p53 Homo sapiens 43-46 18377724-6 2008 CAS overexpression enhanced p53 accumulation induced by doxorubicin, 5-fluorouracil, cisplatin, tamoxifen, and etoposide. Etoposide 111-120 tumor protein p53 Homo sapiens 28-31 18366759-6 2008 Of note is the inhibition of the etoposide-induced activation of p53 under hypoxia. Etoposide 33-42 tumor protein p53 Homo sapiens 65-68 18366759-8 2008 Cluster analysis of data unravels several possible pathways involved in the hypoxia-induced protection against etoposide-induced apoptosis: one of them could be the inhibition of p53 activity under hypoxia since caspase 3 activity parallels Bax and Bak expression profile. Etoposide 111-120 tumor protein p53 Homo sapiens 179-182 18373075-5 2008 However, at a low dose of etoposide (repairable damage), Bid activated the S phase checkpoint through the up-regulation of p21 and p27, which are both p53-independent. Etoposide 26-35 tumor protein p53 Homo sapiens 151-154 18206427-9 2008 Both RIP and TIP played roles in activating non-homologous end joining pathway, while only RIP modulated etoposide-induced cell killing in a p53-dependent manner. Etoposide 105-114 tumor protein p53 Homo sapiens 141-144 18191951-0 2008 Interferonalpha enhances etoposide-induced apoptosis in human osteosarcoma U2OS cells by a p53-dependent pathway. Etoposide 25-34 tumor protein p53 Homo sapiens 91-94 18191951-4 2008 IFNalpha enhanced etoposide-induced growth inhibition and apoptosis in p53-wild U2OS cells but not p53-mutant MG63 cells in a dose- and time-dependent manner. Etoposide 18-27 tumor protein p53 Homo sapiens 71-74 18191951-9 2008 Thus we conclude that IFNalpha enhances etoposide-induced apoptosis in human osteosarcoma U2OS cells by a p53-dependent and caspase-activation pathway. Etoposide 40-49 tumor protein p53 Homo sapiens 106-109 18087215-4 2007 When the H460 human lung cancer cell line was treated with hypoxia and etoposide, a chemotherapy agent that induces double-stranded DNA breaks, the dominant transcriptional response was regulated by DNA damage in a p53-dependent manner. Etoposide 71-80 tumor protein p53 Homo sapiens 215-218 18245478-3 2008 In vitro treatment with etoposide only and in vivo treatment with either etoposide or mitoxantrone induces DNA damage, elevates expression (600-fold) and promotes nuclear translocation of p53, and results in apoptosis of leukemic clam hemocytes. Etoposide 24-33 tumor protein p53 Homo sapiens 188-191 18245478-3 2008 In vitro treatment with etoposide only and in vivo treatment with either etoposide or mitoxantrone induces DNA damage, elevates expression (600-fold) and promotes nuclear translocation of p53, and results in apoptosis of leukemic clam hemocytes. Etoposide 73-82 tumor protein p53 Homo sapiens 188-191 18245478-4 2008 Pretreatment with wheat germ agglutinin followed by etoposide treatment induces DNA damage and elevates p53 expression (893-fold) but does not overcome cytoplasmic sequestration of p53 or induce apoptosis. Etoposide 52-61 tumor protein p53 Homo sapiens 104-107 17932621-11 2008 Under basal growth conditions and in response to the chemotherapeutic agent, etoposide, WIP1 antagonized p53-mediated apoptosis in medulloblastoma cell lines. Etoposide 77-86 tumor protein p53 Homo sapiens 105-108 17310986-11 2007 This was shown by studying DNA damage-induced apoptosis in fibroblasts, the Fas death pathway in HeLa cells that do not express functional p53, and etoposide-induced apoptosis in breast carcinoma cells expressing mutant p53. Etoposide 148-157 tumor protein p53 Homo sapiens 220-223 19383392-0 2007 p53 is required for etoposide-induced apoptosis of human embryonic stem cells. Etoposide 20-29 tumor protein p53 Homo sapiens 0-3 19383392-2 2007 Here we investigate the role of p53 in etoposide-induced apoptosis. Etoposide 39-48 tumor protein p53 Homo sapiens 32-35 19383392-4 2007 Etoposide treatment results in a rapid and extensive induction of apoptosis and leads to a further increase in p53 and PUMA expression as well as Bax processing. Etoposide 0-9 tumor protein p53 Homo sapiens 111-114 19383392-6 2007 hESC stably transduced with p53 shRNA display 80% reduction of endogenous p53 and exhibit an 80% reduction in etoposide-induced apoptosis accompanied by constitutive downregulation of Bax and an attenuated upregulation of PUMA. Etoposide 110-119 tumor protein p53 Homo sapiens 28-31 19383392-8 2007 Our study demonstrates that p53 is required for etoposide-induced apoptosis of hESC and reveals, at least in part, the molecular mechanism of DNA-damage-induced apoptosis in hESC. Etoposide 48-57 tumor protein p53 Homo sapiens 28-31 17681274-5 2007 Here, in p53 negative K562 myeloid leukemia cells, etoposide-induced mitotic catastrophe is shown to be time and/or concentration dependent. Etoposide 51-60 tumor protein p53 Homo sapiens 9-12 17636382-0 2007 New alternative phosphorylation sites on the cyclin dependent kinase 1/cyclin a complex in p53-deficient human cells treated with etoposide: possible association with etoposide-induced apoptosis. Etoposide 130-139 tumor protein p53 Homo sapiens 91-94 17636382-0 2007 New alternative phosphorylation sites on the cyclin dependent kinase 1/cyclin a complex in p53-deficient human cells treated with etoposide: possible association with etoposide-induced apoptosis. Etoposide 167-176 tumor protein p53 Homo sapiens 91-94 17636382-13 2007 These findings suggest novel Cdk1 phosphorylation sites, which appear to be associated with p53-independent cell death following etoposide treatment. Etoposide 129-138 tumor protein p53 Homo sapiens 92-95 18084622-8 2007 Moreover, we noted that in etoposide treated LNCaP cells p53 bound to the promoter region of the AR gene, which contains a potential p53 DNA-binding consensus sequence, in chromatin immunoprecipitation assays. Etoposide 27-36 tumor protein p53 Homo sapiens 57-60 18084622-8 2007 Moreover, we noted that in etoposide treated LNCaP cells p53 bound to the promoter region of the AR gene, which contains a potential p53 DNA-binding consensus sequence, in chromatin immunoprecipitation assays. Etoposide 27-36 tumor protein p53 Homo sapiens 133-136 17894897-8 2007 Etoposide increased p53 activity in all cell lines while hypoxia alone decreased it only in HepG2 cells. Etoposide 0-9 tumor protein p53 Homo sapiens 20-23 17894897-10 2007 Using low density DNA arrays to detect the expression of genes involved in the regulation of apoptosis, etoposide and hypoxia were shown to each influence the expression of numerous genes, many of the ones influenced by etoposide being p53 target genes. Etoposide 104-113 tumor protein p53 Homo sapiens 236-239 17894897-10 2007 Using low density DNA arrays to detect the expression of genes involved in the regulation of apoptosis, etoposide and hypoxia were shown to each influence the expression of numerous genes, many of the ones influenced by etoposide being p53 target genes. Etoposide 220-229 tumor protein p53 Homo sapiens 236-239 17894897-12 2007 CONCLUSION: These results evidenced that there was a striking parallelism between the effect of hypoxia on the etoposide-induced p53 stabilization as well as p53 target gene expression and its effect on the etoposide-induced apoptosis according to the cell type. Etoposide 111-120 tumor protein p53 Homo sapiens 129-132 17894897-12 2007 CONCLUSION: These results evidenced that there was a striking parallelism between the effect of hypoxia on the etoposide-induced p53 stabilization as well as p53 target gene expression and its effect on the etoposide-induced apoptosis according to the cell type. Etoposide 207-216 tumor protein p53 Homo sapiens 129-132 17894897-12 2007 CONCLUSION: These results evidenced that there was a striking parallelism between the effect of hypoxia on the etoposide-induced p53 stabilization as well as p53 target gene expression and its effect on the etoposide-induced apoptosis according to the cell type. Etoposide 207-216 tumor protein p53 Homo sapiens 158-161 17515610-6 2007 Suppression of Rad51 expression, required for homologous recombination repair, blocked the ability of mutant p53 to antagonize arrest induced by etoposide, but not aphidicolin. Etoposide 145-154 tumor protein p53 Homo sapiens 109-112 17515610-8 2007 However, when replication stress is associated with DNA strand breaks (such as with etoposide), up-regulation of homologous recombination repair in response to p53 disruption becomes important. Etoposide 84-93 tumor protein p53 Homo sapiens 160-163 17630856-0 2007 Absence of p53 enhances growth defects and etoposide sensitivity of human cells lacking the Bloom syndrome helicase BLM. Etoposide 43-52 tumor protein p53 Homo sapiens 11-14 17699715-4 2007 Etoposide-selective cytotoxicity in the Akt-myr-transduced cells was shown to be caused by nonapoptotic cell death and occurred in a p53-independent manner. Etoposide 0-9 tumor protein p53 Homo sapiens 133-136 17630856-5 2007 Our results suggest a direct, BLM-independent role for p53 in etoposide-induced, topoisomerase II-mediated DNA damage in human cells. Etoposide 62-71 tumor protein p53 Homo sapiens 55-58 16971506-10 2006 p53 phosphorylation was induced by serum withdrawal and other chemotherapeutic reagents such as actinomycin D, doxorubicin, and etoposide. Etoposide 128-137 tumor protein p53 Homo sapiens 0-3 17057733-7 2007 This transactivation was enhanced by etoposide, a DNA damaging agent that activates p53 and was completely blocked by a dominant-negative p53 mutant. Etoposide 37-46 tumor protein p53 Homo sapiens 84-87 17057733-7 2007 This transactivation was enhanced by etoposide, a DNA damaging agent that activates p53 and was completely blocked by a dominant-negative p53 mutant. Etoposide 37-46 tumor protein p53 Homo sapiens 138-141 16971507-0 2006 Proteasome inhibitors potentiate etoposide-induced cell death in human astrocytoma cells bearing a mutated p53 isoform. Etoposide 33-42 tumor protein p53 Homo sapiens 107-110 17047058-5 2006 By contrast, etoposide activated p53 and down-regulated hTERT promoter activity in normal cells. Etoposide 13-22 tumor protein p53 Homo sapiens 33-36 16931776-10 2006 In vitro exposure of hMSCs to cisplatin, vincristine, and etoposide resulted in an increased p53 expression, independent of apoptosis induction. Etoposide 58-67 tumor protein p53 Homo sapiens 93-96 16882877-4 2006 The induction of WI38 cell senescence by Etop was associated with p53 activation and could be attenuated by down-regulation of p53 using alpha-pifithrin (alpha-PFT) or p53 small interference RNA (siRNA). Etoposide 41-45 tumor protein p53 Homo sapiens 66-69 16882877-4 2006 The induction of WI38 cell senescence by Etop was associated with p53 activation and could be attenuated by down-regulation of p53 using alpha-pifithrin (alpha-PFT) or p53 small interference RNA (siRNA). Etoposide 41-45 tumor protein p53 Homo sapiens 127-130 16882877-4 2006 The induction of WI38 cell senescence by Etop was associated with p53 activation and could be attenuated by down-regulation of p53 using alpha-pifithrin (alpha-PFT) or p53 small interference RNA (siRNA). Etoposide 41-45 tumor protein p53 Homo sapiens 127-130 17121917-6 2006 In line with our previous data, statins were found to attenuate the etoposide-induced p53 response. Etoposide 68-77 tumor protein p53 Homo sapiens 86-89 16797759-3 2006 By Western blot, the expression of 14-3-3sigma, p53 and p21 was coordinately upregulated in astrocytes following exposure to hydrogen peroxide, 4-hydroxy-2-nonenal (4-HNE) or etoposide, a topoisomerase II inhibitor. Etoposide 175-184 tumor protein p53 Homo sapiens 48-51 16598770-8 2006 The over-expression of p53 protein in the etoposide treated cells indicated a significant level of DNA fragmentation and apoptosis. Etoposide 42-51 tumor protein p53 Homo sapiens 23-26 16797759-6 2006 Microarray analysis of etoposide-treated astrocytes verified upregulation of p53-responsive genes and concurrent downregulation of mitotic checkpoint-regulatory genes. Etoposide 23-32 tumor protein p53 Homo sapiens 77-80 16325212-6 2006 Together, our data indicate that p33ING1b prominently enhances etoposide-induced apoptosis through p53-dependent pathways in human osteosarcoma cells. Etoposide 63-72 tumor protein p53 Homo sapiens 99-102 16607284-5 2006 We show that p53 synthesis increases dramatically in MCF-7 cells treated with etoposide. Etoposide 78-87 tumor protein p53 Homo sapiens 13-16 16847267-4 2006 Here we present evidence indicating that MageA2 protein, belonging to the MAGE-A subfamily, confers wild-type-p53-sensitive resistance to etoposide (ET) by inducing a novel p53 inhibitory loop involving recruitment of histone deacetylase 3 (HDAC3) to MageA2/p53 complex, thus strongly down-regulating p53 transactivation function. Etoposide 138-147 tumor protein p53 Homo sapiens 110-113 16847267-4 2006 Here we present evidence indicating that MageA2 protein, belonging to the MAGE-A subfamily, confers wild-type-p53-sensitive resistance to etoposide (ET) by inducing a novel p53 inhibitory loop involving recruitment of histone deacetylase 3 (HDAC3) to MageA2/p53 complex, thus strongly down-regulating p53 transactivation function. Etoposide 138-147 tumor protein p53 Homo sapiens 173-176 16847267-4 2006 Here we present evidence indicating that MageA2 protein, belonging to the MAGE-A subfamily, confers wild-type-p53-sensitive resistance to etoposide (ET) by inducing a novel p53 inhibitory loop involving recruitment of histone deacetylase 3 (HDAC3) to MageA2/p53 complex, thus strongly down-regulating p53 transactivation function. Etoposide 138-147 tumor protein p53 Homo sapiens 173-176 16847267-4 2006 Here we present evidence indicating that MageA2 protein, belonging to the MAGE-A subfamily, confers wild-type-p53-sensitive resistance to etoposide (ET) by inducing a novel p53 inhibitory loop involving recruitment of histone deacetylase 3 (HDAC3) to MageA2/p53 complex, thus strongly down-regulating p53 transactivation function. Etoposide 138-147 tumor protein p53 Homo sapiens 173-176 16847267-4 2006 Here we present evidence indicating that MageA2 protein, belonging to the MAGE-A subfamily, confers wild-type-p53-sensitive resistance to etoposide (ET) by inducing a novel p53 inhibitory loop involving recruitment of histone deacetylase 3 (HDAC3) to MageA2/p53 complex, thus strongly down-regulating p53 transactivation function. Etoposide 149-151 tumor protein p53 Homo sapiens 110-113 16847267-4 2006 Here we present evidence indicating that MageA2 protein, belonging to the MAGE-A subfamily, confers wild-type-p53-sensitive resistance to etoposide (ET) by inducing a novel p53 inhibitory loop involving recruitment of histone deacetylase 3 (HDAC3) to MageA2/p53 complex, thus strongly down-regulating p53 transactivation function. Etoposide 149-151 tumor protein p53 Homo sapiens 173-176 16847267-4 2006 Here we present evidence indicating that MageA2 protein, belonging to the MAGE-A subfamily, confers wild-type-p53-sensitive resistance to etoposide (ET) by inducing a novel p53 inhibitory loop involving recruitment of histone deacetylase 3 (HDAC3) to MageA2/p53 complex, thus strongly down-regulating p53 transactivation function. Etoposide 149-151 tumor protein p53 Homo sapiens 173-176 16847267-4 2006 Here we present evidence indicating that MageA2 protein, belonging to the MAGE-A subfamily, confers wild-type-p53-sensitive resistance to etoposide (ET) by inducing a novel p53 inhibitory loop involving recruitment of histone deacetylase 3 (HDAC3) to MageA2/p53 complex, thus strongly down-regulating p53 transactivation function. Etoposide 149-151 tumor protein p53 Homo sapiens 173-176 16847267-7 2006 In addition, combined trichostatin A/ET treatment in melanoma cells expressing high MAGE-A levels reestablishes p53 response and reverts the chemoresistance. Etoposide 37-39 tumor protein p53 Homo sapiens 112-115 16547931-0 2006 The course of etoposide-induced apoptosis in Jurkat cells lacking p53 and Bax. Etoposide 14-23 tumor protein p53 Homo sapiens 66-69 16799873-11 2006 Cyclin A1 but not cyclin A2 was upregulated in etoposide-treated tumor cells undergoing p53-dependent apoptosis and mitotic catastrophe. Etoposide 47-56 tumor protein p53 Homo sapiens 88-91 16827139-7 2006 ZBP-89 potentiated p53-mediated cell death with 10 nM staurosporine and 100 nM etoposide, but did not in the presence of the R273H p53 mutation. Etoposide 79-88 tumor protein p53 Homo sapiens 19-22 16527552-9 2006 Phospho-ERK1/2, Akt activity and expression of c-Myc were significantly induced by etoposide in a time-dependent manner; moreover, there was a weak effect on the expression of p53 protein. Etoposide 83-92 tumor protein p53 Homo sapiens 176-179 16325212-0 2006 The p33ING1b tumor suppressor cooperates with p53 to induce apoptosis in response to etoposide in human osteosarcoma cells. Etoposide 85-94 tumor protein p53 Homo sapiens 46-49 16325212-4 2006 p33ING1b increased etoposide-induced growth inhibition and apoptosis to a much greater degree in p53+/+ U2OS cells than in p53-mutant MG63 cells. Etoposide 19-28 tumor protein p53 Homo sapiens 97-100 16093994-0 2005 Differential regulation of p21waf-1/cip-1 and Mdm2 by etoposide: etoposide inhibits the p53-Mdm2 autoregulatory feedback loop. Etoposide 65-74 tumor protein p53 Homo sapiens 88-91 16568831-12 2006 Both cell lines exhibited high sensitivity to etoposide, classical inductor of unrepairable DSBs and p53. Etoposide 46-55 tumor protein p53 Homo sapiens 101-104 16467399-5 2006 In JAR cells, etoposide increased expression of the proteins including IFNgammaR, p53 and pro-caspase 3 as well as IRF-1 mRNA and IFNgamma-pretreatment apparently promoted up-regulation of these molecules expression. Etoposide 14-23 tumor protein p53 Homo sapiens 82-85 16219768-4 2005 Here, we determined that UV light, anisomycin, etoposide, and hypoxic stress rapidly induced phosphorylation of p53 at Ser46 and WOX1 at Tyr33 (phospho-WOX1) and their binding interactions in several tested cancer cells. Etoposide 47-56 tumor protein p53 Homo sapiens 112-115 16260623-3 2005 Compared to vector-transfected cells, H1299 cells expressing mutant p53 showed a survival advantage when treated with etoposide, a common chemotherapeutic agent; however, cells expressing the transactivation-deficient triple mutant p53-D281G (L22Q/W23S) had significantly lower resistance to etoposide. Etoposide 118-127 tumor protein p53 Homo sapiens 68-71 16260623-3 2005 Compared to vector-transfected cells, H1299 cells expressing mutant p53 showed a survival advantage when treated with etoposide, a common chemotherapeutic agent; however, cells expressing the transactivation-deficient triple mutant p53-D281G (L22Q/W23S) had significantly lower resistance to etoposide. Etoposide 292-301 tumor protein p53 Homo sapiens 68-71 16260623-6 2005 Treatment of H1299 cells expressing p53-R175H with small interfering RNA specific for NF-kappaB2 made these cells more sensitive to etoposide. Etoposide 132-141 tumor protein p53 Homo sapiens 36-39 16202244-3 2005 Here we showed that etoposide can induce the similar degree of cell death in p53-deficient HCT 116 cells, whereas 5"-FU-mediated cell death is strongly dependent on the existence of functional p53 in HCT 116 cells. Etoposide 20-29 tumor protein p53 Homo sapiens 77-80 16202244-5 2005 These data suggest that etoposide can directly induce the mitochondrial dysfunction irrespective of p53 status, and it may, at least in part, account for the p53-independent pathway in cell death induced by chemotherapeutic agents. Etoposide 24-33 tumor protein p53 Homo sapiens 158-161 16093994-0 2005 Differential regulation of p21waf-1/cip-1 and Mdm2 by etoposide: etoposide inhibits the p53-Mdm2 autoregulatory feedback loop. Etoposide 54-63 tumor protein p53 Homo sapiens 88-91 15914462-8 2005 Treatment of colon and ovarian carcinoma cells with the anticancer genotoxic agent etoposide up-regulated both p53 and proline oxidase, activated calcineurin, and induced apoptosis. Etoposide 83-92 tumor protein p53 Homo sapiens 111-114 16120219-7 2005 Both etoposide and CLP induced an accumulation of p53 protein and upregulation of p53 transcriptional target genes. Etoposide 5-14 tumor protein p53 Homo sapiens 50-53 16120219-7 2005 Both etoposide and CLP induced an accumulation of p53 protein and upregulation of p53 transcriptional target genes. Etoposide 5-14 tumor protein p53 Homo sapiens 82-85 16277093-0 2005 Expression of p53 protein and DNA flow cytometry in gastric adenocarcinoma: implications in patients treated with adjuvant etoposide, adriamycin and cisplatin. Etoposide 123-132 tumor protein p53 Homo sapiens 14-17 15908423-4 2005 Nuclear accumulation of p53 protein in mdm2 SNP309 cells results after 6 h of camptothecin, etoposide, or mitomycin C treatment, with the p53 protein phosphorylated at Ser15. Etoposide 92-101 tumor protein p53 Homo sapiens 24-27 15832344-0 2005 JNK/p53 mediated cell death response in K562 exposed to etoposide-ionizing radiation combined treatment. Etoposide 56-65 tumor protein p53 Homo sapiens 4-7 15896459-0 2005 Etoposide (VP-16) elicits apoptosis following prolonged G2-M cell arrest in p53-mutated human non-small cell lung cancer cells. Etoposide 0-9 tumor protein p53 Homo sapiens 76-79 15896459-1 2005 In this work, we described the proliferation of human non-small-cell-lung-cancer (NSCLC) cells H1437 harboring p53 alleles (proline-267) can be inhibited by low-dosage topoisomerase II inhibitor etoposide (VP-16) in vitro and in vivo. Etoposide 195-204 tumor protein p53 Homo sapiens 111-114 15832344-5 2005 Moreover, p53 is a potential substrate for JNK and may act as a JNK target for etoposide and ionizing radiation. Etoposide 79-88 tumor protein p53 Homo sapiens 10-13 15846088-5 2005 The cell line that showed greatest reduction (85-90%) of p53 expression showed decreased p21 promoter activation after DNA damage with camptothecin, etoposide and MMS. Etoposide 149-158 tumor protein p53 Homo sapiens 57-60 15909125-0 2005 Etoposide (VP-16) sensitizes p53-deficient human non-small cell lung cancer cells to caspase-7-mediated apoptosis. Etoposide 0-9 tumor protein p53 Homo sapiens 29-32 15674334-6 2005 The camptothecin or etoposide-dependent p53-mediated repression was attenuated by trichostatin A (TSA), an inhibitor of histone deacetylases (HDACs). Etoposide 20-29 tumor protein p53 Homo sapiens 40-43 15543231-8 2005 At the opposite, upon treatment with topoisomerase II inhibitors (doxorubicin or etoposide), the expression of TAp63 isoforms was clearly induced, independently of the TP53 status of cells. Etoposide 81-90 tumor protein p53 Homo sapiens 168-172 15345715-8 2004 Treatment of fibroblasts with etoposide, a potent inducer of cellular p53, abrogated TGF-beta stimulation of COL1A2 promoter activity and collagen synthesis in a p53-dependent manner. Etoposide 30-39 tumor protein p53 Homo sapiens 70-73 15829155-10 2005 Etoposide increased the expression of wild-type p53, activated CPP32 (but not ICE) activity, and induced apoptosis in these cells. Etoposide 0-9 tumor protein p53 Homo sapiens 48-51 15471885-6 2004 Comparison of the activity of unphosphorylated and phosphorylated p53 induced by the genotoxic drugs doxorubicin and etoposide in HCT116 and RKO cells revealed no difference in their sequence-specific DNA binding and ability to transactivate p53 target genes and to induce p53-dependent apoptosis. Etoposide 117-126 tumor protein p53 Homo sapiens 66-69 15345715-8 2004 Treatment of fibroblasts with etoposide, a potent inducer of cellular p53, abrogated TGF-beta stimulation of COL1A2 promoter activity and collagen synthesis in a p53-dependent manner. Etoposide 30-39 tumor protein p53 Homo sapiens 162-165 15117953-3 2004 We report here that the BH3-only Bcl-2 family member Bid is required for mitochondrial permeabilization and apoptosis induction by etoposide and gamma-radiation in p53 mutant T leukemic cells. Etoposide 131-140 tumor protein p53 Homo sapiens 164-167 14742315-5 2004 Consistent with the proposed role of p53 as a suppressor of error-prone recombination, both p53 proteins down-regulated recombination with most of the sequences tested, even with the MLL bcr after etoposide treatment. Etoposide 197-206 tumor protein p53 Homo sapiens 92-95 15475000-7 2004 Moreover, the overexpression of an inactivated GSK-3beta mutant counteracted the stimulatory effects of etoposide and camptothecin on a luciferase reporter plasmid driven by a p53-responsive sequence from the CD95 gene. Etoposide 104-113 tumor protein p53 Homo sapiens 176-179 14660748-9 2003 Furthermore, we showed that c-myc-overexpressing cells retain a functional p53 pathway and thus respond to etoposide. Etoposide 107-116 tumor protein p53 Homo sapiens 75-78 15191662-11 2004 CONCLUSION: These observations suggest that p33(ING1b) up-regulates p53 protein, and cooperate with p53 in stimulating expression of p21(WAF1) and Bax gene, thus to enhance etoposide-induced apoptosis via p53-dependent pathways. Etoposide 173-182 tumor protein p53 Homo sapiens 100-103 15191662-11 2004 CONCLUSION: These observations suggest that p33(ING1b) up-regulates p53 protein, and cooperate with p53 in stimulating expression of p21(WAF1) and Bax gene, thus to enhance etoposide-induced apoptosis via p53-dependent pathways. Etoposide 173-182 tumor protein p53 Homo sapiens 100-103 15201971-1 2004 We have previously shown that treatment of human glioma U87-MG cells expressing wild-type p53 with a DNA topoisomerase II inhibitor, etoposide resulted in ceramide-dependent apoptotic cell death. Etoposide 133-142 tumor protein p53 Homo sapiens 90-93 14988151-6 2004 Furthermore, p53 gene silencing resulted in decreased p21 mRNA levels and reduced the sensitivity of CD34+ cells toward the cytotoxic drug etoposide. Etoposide 139-148 tumor protein p53 Homo sapiens 13-16 12874009-2 2003 Here, we investigate the role of p53 in the G(2) arrest that occurs in response to the topoisomerase inhibitors etoposide and merbarone. Etoposide 112-121 tumor protein p53 Homo sapiens 33-36 14583449-5 2003 Interestingly, ionizing radiation or etoposide, both of which stabilize and activate p53, diminished p53 binding in chromatin immunoprecipitation assays, concomitant with a 5-fold increase in Dnmt1 levels. Etoposide 37-46 tumor protein p53 Homo sapiens 85-88 14583449-5 2003 Interestingly, ionizing radiation or etoposide, both of which stabilize and activate p53, diminished p53 binding in chromatin immunoprecipitation assays, concomitant with a 5-fold increase in Dnmt1 levels. Etoposide 37-46 tumor protein p53 Homo sapiens 101-104 12907245-0 2003 The JNK, ERK and p53 pathways play distinct roles in apoptosis mediated by the antitumor agents vinblastine, doxorubicin, and etoposide. Etoposide 126-135 tumor protein p53 Homo sapiens 17-20 12874009-3 2003 In HT1080 cells expressing a dominant-negative form of p53, treatment with etoposide still caused G(2) arrest, but the arrest could be overcome by additional treatment with caffeine, which inhibits the damage-responsive kinases ataxia telangiectasia mutated (ATM) and atm and rad3-related (ATR). Etoposide 75-84 tumor protein p53 Homo sapiens 55-58 12874009-5 2003 We conclude that etoposide activates two pathways, one of which depends on p53 and the other of which is sensitive to caffeine, and that either pathway is sufficient to activate G(2) arrest. Etoposide 17-26 tumor protein p53 Homo sapiens 75-78 12767922-2 2003 Here we show that topoisomerase II inhibitors, genistein and etoposide, induce p21(WAF1/Cip1) expression mainly in a p53-dependent manner in human lung cancer cell line A549. Etoposide 61-70 tumor protein p53 Homo sapiens 117-120 12767922-6 2003 These data suggest that both genistein and etoposide induce p21(WAF1/Cip1) expression in a p53-dependent manner. Etoposide 43-52 tumor protein p53 Homo sapiens 91-94 12738983-7 2003 After genotoxic stress such as etoposide treatment, AS2 expressing cells readily progressed into apoptosis through p53 and caspase-3 activations. Etoposide 31-40 tumor protein p53 Homo sapiens 115-118 12773551-4 2003 p53 response to treatment with gamma irradiation or etoposide is lost due to a mutation at codon 242 of p53 (C-->W). Etoposide 52-61 tumor protein p53 Homo sapiens 104-107 12468545-5 2003 After treatment with Vp16 or mitomycin C, control cells underwent apoptosis in a p53-dependent manner; however, overexpression of catalase inhibited this apoptosis. Etoposide 21-25 tumor protein p53 Homo sapiens 81-84 12771025-6 2003 Furthermore, northern analysis showed that induction of this gene is independent of p53, as increased expression of the gene was observed in p53 null H1299/Neo control cells when the temperature was shifted to 32 degrees C. Moreover, a DNA damaging agent, etoposide, also induced beta1 subunit expression in multiple human tumor cells, regardless of p53 status. Etoposide 256-265 tumor protein p53 Homo sapiens 141-144 12771025-6 2003 Furthermore, northern analysis showed that induction of this gene is independent of p53, as increased expression of the gene was observed in p53 null H1299/Neo control cells when the temperature was shifted to 32 degrees C. Moreover, a DNA damaging agent, etoposide, also induced beta1 subunit expression in multiple human tumor cells, regardless of p53 status. Etoposide 256-265 tumor protein p53 Homo sapiens 141-144 12771025-7 2003 Thus, the beta1 subunit of AMPK is not a p53 downstream target gene, but can be induced by cold shock or the chemotherapeutic drug, etoposide in a p53-independent manner. Etoposide 132-141 tumor protein p53 Homo sapiens 147-150 12684687-4 2003 We report that Brca1-deficiency in p53-null cells was associated with increased sensitivity to the topoisomerase I poisons camptothecin and topotecan, the topoisomerase II poisons doxorubicin, mitoxantrone and etoposide, and to the platinum compounds carboplatin and oxaliplatin, but not to the antimetabolites 5-fluorouracil and gemcitabine and the taxanes docetaxel and paclitaxel. Etoposide 210-219 tumor protein p53 Homo sapiens 35-38 12712406-0 2003 c-Jun NH2-terminal kinase-dependent Fas activation contributes to etoposide-induced apoptosis in p53-mutated prostate cancer cells. Etoposide 66-75 tumor protein p53 Homo sapiens 97-100 12644023-8 2003 CONCLUSION: p53, c-Myc, and BAFF pathways are main pathways utilized by CD34(+) cells to arrest cell-cycle progression at multiple checkpoints, to halt proliferation, and to induce apoptosis as part of their cellular response to etoposide. Etoposide 229-238 tumor protein p53 Homo sapiens 12-15 11827710-0 2002 Pifithrin-alpha, an inhibitor of p53, enhances the genetic instability induced by etoposide (VP16) in human lymphoblastoid cells treated in vitro. Etoposide 82-91 tumor protein p53 Homo sapiens 33-36 15314976-0 2003 Expression of p53 gene in stage IIIA non-small cell lung cancer in patients after neoadjuvant chemotherapy with Vepesid and Cisplatin. Etoposide 112-119 tumor protein p53 Homo sapiens 14-17 12389116-14 2002 Etoposide and vinblastine were found to effectively inactivate the androgen-independent cell lines, in which p53 is dysfunctional. Etoposide 0-9 tumor protein p53 Homo sapiens 109-112 11864976-0 2002 The course of etoposide-induced apoptosis from damage to DNA and p53 activation to mitochondrial release of cytochrome c. Etoposide 14-23 tumor protein p53 Homo sapiens 65-68 11864976-3 2002 Etoposide caused the phosphorylation of p53 within 6 h, an effect prevented by wortmannin, an inhibitor of DNA-dependent protein kinase (DNA-PK). Etoposide 0-9 tumor protein p53 Homo sapiens 40-43 11864976-4 2002 The activation of p53 by etoposide resulted in the up-regulation of the pro-apoptotic protein Bax, a result that was prevented by the protein synthesis inhibitor cycloheximide. Etoposide 25-34 tumor protein p53 Homo sapiens 18-21 11935300-6 2002 RESULTS: Ex vivo chemosensitivity testing showed that tumors with p53 mutations were significantly more resistant to the cyclophosphamide/etoposide/epirubicin regimen than with normal p53 gene ( P = 0.012). Etoposide 138-147 tumor protein p53 Homo sapiens 66-69 12509267-10 2003 p53 deficient cells were cross-resistant to another topoisomerase II inhibitor etoposide, which also provoked increased DNA strand breakage in p53 wt cells. Etoposide 79-88 tumor protein p53 Homo sapiens 0-3 12509267-10 2003 p53 deficient cells were cross-resistant to another topoisomerase II inhibitor etoposide, which also provoked increased DNA strand breakage in p53 wt cells. Etoposide 79-88 tumor protein p53 Homo sapiens 143-146 11827710-0 2002 Pifithrin-alpha, an inhibitor of p53, enhances the genetic instability induced by etoposide (VP16) in human lymphoblastoid cells treated in vitro. Etoposide 93-97 tumor protein p53 Homo sapiens 33-36 11841447-7 2002 We found that the expression of the cell cycle checkpoint protein Chk1 was reduced in the etoposide-treated p53-transfected cells by 24 h, and this correlated with a reduction in the extent of etoposide-induced phosphorylation of CDK1 at tyrosine 15 (Y15). Etoposide 193-202 tumor protein p53 Homo sapiens 108-111 11841447-4 2002 The p53-transfected cells showed a decreased ability to arrest in G2 and an increase in apoptosis in response to etoposide treatment, relative to the control mock-transfected cells. Etoposide 113-122 tumor protein p53 Homo sapiens 4-7 11841447-5 2002 p53-transfected and control cells were treated with etoposide and trapped at mitosis with nocodazole. Etoposide 52-61 tumor protein p53 Homo sapiens 0-3 11841447-6 2002 The mitotic index of p53-transfected cells was higher than that of the control cells, which suggests that p53 abrogates the G2 checkpoint response to etoposide treatment in K562 cells. Etoposide 150-159 tumor protein p53 Homo sapiens 21-24 11841447-6 2002 The mitotic index of p53-transfected cells was higher than that of the control cells, which suggests that p53 abrogates the G2 checkpoint response to etoposide treatment in K562 cells. Etoposide 150-159 tumor protein p53 Homo sapiens 106-109 11841447-7 2002 We found that the expression of the cell cycle checkpoint protein Chk1 was reduced in the etoposide-treated p53-transfected cells by 24 h, and this correlated with a reduction in the extent of etoposide-induced phosphorylation of CDK1 at tyrosine 15 (Y15). Etoposide 90-99 tumor protein p53 Homo sapiens 108-111 11841447-8 2002 We conclude, therefore, that p53 overrides the strong G2 checkpoint response to etoposide in K562 cells, by directly or indirectly downregulating Chk1 expression, which, in turn, contributes to the proapoptotic effect of p53. Etoposide 80-89 tumor protein p53 Homo sapiens 29-32 11841447-8 2002 We conclude, therefore, that p53 overrides the strong G2 checkpoint response to etoposide in K562 cells, by directly or indirectly downregulating Chk1 expression, which, in turn, contributes to the proapoptotic effect of p53. Etoposide 80-89 tumor protein p53 Homo sapiens 221-224 11791171-5 2002 In PA1-neo cells with wild-type p53, the activation of caspases including caspases 9, 8, 7 and 3 and cleavage of PARP were detected following adriamycin or etoposide treatment, whereas no such changes were observed in PA1-E6 cells whose p53 is degraded, suggesting that loss of p53 impairs caspase activation. Etoposide 156-165 tumor protein p53 Homo sapiens 32-35 11791171-5 2002 In PA1-neo cells with wild-type p53, the activation of caspases including caspases 9, 8, 7 and 3 and cleavage of PARP were detected following adriamycin or etoposide treatment, whereas no such changes were observed in PA1-E6 cells whose p53 is degraded, suggesting that loss of p53 impairs caspase activation. Etoposide 156-165 tumor protein p53 Homo sapiens 237-240 11791171-5 2002 In PA1-neo cells with wild-type p53, the activation of caspases including caspases 9, 8, 7 and 3 and cleavage of PARP were detected following adriamycin or etoposide treatment, whereas no such changes were observed in PA1-E6 cells whose p53 is degraded, suggesting that loss of p53 impairs caspase activation. Etoposide 156-165 tumor protein p53 Homo sapiens 237-240 11684284-0 2001 p53 and redox state in etoposide-induced acute myeloblastic leukemia cell death. Etoposide 23-32 tumor protein p53 Homo sapiens 0-3 12429914-5 2002 BL also inhibited the p53-dependent increase of p21 protein expression in cells exposed to the DNA damag-ing agent etoposide, and favored a greater G2/M arrest as compared to the non-BL exposed cells. Etoposide 115-124 tumor protein p53 Homo sapiens 22-25 11684284-1 2001 We investigated whether p53, being a redox-sensitive protein, has a role in the responsiveness of AML cells to etoposide. Etoposide 111-120 tumor protein p53 Homo sapiens 24-27 11684284-6 2001 After etoposide exposure for up to 24 hours, some nuclear accumulation of p53 was observed in the ER subclone, as analysed by Western blotting. Etoposide 6-15 tumor protein p53 Homo sapiens 74-77 11576999-13 2001 Since over 50% of human tumors contain a functionally defective p53 that reduces sensitivity to commonly used chemotherapeutic agents, such as etoposide and cisplatin, the ability of tachpyridine to induce apoptosis independently of p53 may offer an advantage in anti-tumor therapy. Etoposide 143-152 tumor protein p53 Homo sapiens 64-67 11698292-9 2001 In contrast, in vitro treatment with cytarabine and etoposide induced p53 protein, CD95 receptor expression, CD95 sensitivity, and CD95 receptor-ligand interaction in stimulated cycling lymphocytes, but no such induction was seen in resting cells. Etoposide 52-61 tumor protein p53 Homo sapiens 70-73 11498763-12 2001 In addition, we determined the effects of DNA damage produced by the DNA topoisomerase II inhibitor etoposide on wild-type p53 transfected lymphoma cells. Etoposide 100-109 tumor protein p53 Homo sapiens 123-126 11507071-9 2001 Loss of p53 function was selectively achieved by transduction of human papillomavirus 16 E6 (which degrades p53) into two drug-sensitive neuroblastoma cell lines with intact p53, causing high-level drug resistance to L-PAM, carboplatin, and etoposide. Etoposide 241-250 tumor protein p53 Homo sapiens 8-11 11313880-7 2001 In contrast, human glioma cells lacking functional p53, either due to mutation or the expression of E6 protein of human papillomavirus, were highly resistant to etoposide and exhibited no significant change in the ceramide level. Etoposide 161-170 tumor protein p53 Homo sapiens 51-54 11484935-2 2001 We found that four anticancer agents: etoposide, doxorubicin, bleomycin and paclitaxel induced apoptosis in human umbilical vein endothelial cells (HUVECs) (as judged by DNA fragmentation) with a time- and concentration-dependent decrease in bcl-2 protein but without the involvement of p53. Etoposide 38-47 tumor protein p53 Homo sapiens 287-290 11306736-4 2001 When HL-60 cells, p53 null, were treated with etoposide, MDM2 was markedly decreased prior to caspase-3-dependent retinoblastoma tumor suppressor protein (pRb) and poly (ADP- ribose) polymerase (PARP) cleavages. Etoposide 46-55 tumor protein p53 Homo sapiens 18-21 11387205-2 2001 Here we provide evidence that overexpression of Gas2 efficiently increases cell susceptibility to apoptosis following UV irradiation, etoposide and methyl methanesulfonate treatments, and that these effects are dependent on increased p53 stability and transcription activity. Etoposide 134-143 tumor protein p53 Homo sapiens 234-237 11482451-8 2001 In the TP53 mutant cell lines, DU145 and BM1604, dose enhancement factors (EFs) were found to be in the region of 4.20 for cisplatin, 3.70 for vinblastine, and 3.20 for etoposide. Etoposide 169-178 tumor protein p53 Homo sapiens 7-11 11482451-9 2001 In the TP53 wild-type cell line, LNCaP, the enhancement factors were low and in the region of 1.20 for cisplatin, vinblastine and etoposide. Etoposide 130-139 tumor protein p53 Homo sapiens 7-11 11400161-9 2001 Induction of endogenous p53 expression by etoposide also inhibited promoter activity and minigene inducibility. Etoposide 42-51 tumor protein p53 Homo sapiens 24-27 11346470-5 2001 Treatment with etoposide increased expression of p53 and decreased expression of Bcl-X(L) in U-373MG cells which harbored mutant p53. Etoposide 15-24 tumor protein p53 Homo sapiens 49-52 11346470-5 2001 Treatment with etoposide increased expression of p53 and decreased expression of Bcl-X(L) in U-373MG cells which harbored mutant p53. Etoposide 15-24 tumor protein p53 Homo sapiens 129-132 11401473-6 2001 Accumulation of P53 and its target gene bax then sensitized HeLa cells to cell-cycle arrest, cell death/apoptosis induced by cisplatin, and etoposide. Etoposide 140-149 tumor protein p53 Homo sapiens 16-19 11313880-2 2001 Treatment of human glioma cells with etoposide caused apoptosis only in cells expressing functional p53. Etoposide 37-46 tumor protein p53 Homo sapiens 100-103 11090076-8 2000 These findings indicate that treatment with etoposide, Ara-C, or doxorubicin up-regulates DR5 levels in a p53-independent manner and sensitizes human acute leukemia cells to Apo-2L-induced apoptosis. Etoposide 44-53 tumor protein p53 Homo sapiens 106-109 11096068-7 2001 In contrast, the topoisomerase II inhibitor etoposide induced phosphorylation of p53 and Chk2 in ATM-positive and ATM-deficient cells. Etoposide 44-53 tumor protein p53 Homo sapiens 81-84 11125034-0 2001 MDM2 mediated nuclear exclusion of p53 attenuates etoposide-induced apoptosis in neuroblastoma cells. Etoposide 50-59 tumor protein p53 Homo sapiens 35-38 11125034-3 2001 Data presented here indicate that hyperactive nuclear export of p53 suppresses etoposide-induced apoptosis but does not prevent growth arrest. Etoposide 79-88 tumor protein p53 Homo sapiens 64-67 11125034-5 2001 Our data show etoposide induces complete trans-location of p53 to the nucleus and activation of apoptosis in the neuroblastic NB cell line SH-SY5Y (N-type), which expresses low levels of MDM2. Etoposide 14-23 tumor protein p53 Homo sapiens 59-62 11125034-11 2001 These results demonstrate for the first time that hyperactive nuclear export of p53 attenuates chemotherapy-induced apoptosis in NB cells, and our findings suggest that inhibitors of MDM2 may enhance the therapeutic efficacy of etoposide by promoting apoptosis rather than trans-differentiation. Etoposide 228-237 tumor protein p53 Homo sapiens 80-83 10996201-8 2000 Our findings suggest that down regulation of topo IIalpha in association with p53 deficiency can confer chromosomal instability in etoposide-resistant K562 cells. Etoposide 131-140 tumor protein p53 Homo sapiens 78-81 10993652-4 2000 The p53(+)/RB(-)cells were susceptible to apoptosis under various experimental conditions: 1) incubation in serum-free culture for 72 h, 2) short-term (6 h) or long-term (48 h) exposure to etoposide, and 3) culturing in soft agar. Etoposide 189-198 tumor protein p53 Homo sapiens 4-7 11005251-5 2000 In etoposide model with chip hybridization, we defined signaling pathways that mediate apoptosis in p53 dependent manner (through activation of p53 target genes such as Waf-1/p21, PCNA, GPX, S100A2 and PTGF-beta) as well as in p53-independent manner (through activation of ODC and TGF-beta receptor, among others). Etoposide 3-12 tumor protein p53 Homo sapiens 100-103 11005251-5 2000 In etoposide model with chip hybridization, we defined signaling pathways that mediate apoptosis in p53 dependent manner (through activation of p53 target genes such as Waf-1/p21, PCNA, GPX, S100A2 and PTGF-beta) as well as in p53-independent manner (through activation of ODC and TGF-beta receptor, among others). Etoposide 3-12 tumor protein p53 Homo sapiens 144-147 11005251-5 2000 In etoposide model with chip hybridization, we defined signaling pathways that mediate apoptosis in p53 dependent manner (through activation of p53 target genes such as Waf-1/p21, PCNA, GPX, S100A2 and PTGF-beta) as well as in p53-independent manner (through activation of ODC and TGF-beta receptor, among others). Etoposide 3-12 tumor protein p53 Homo sapiens 144-147 10811471-4 2000 Ad-p53 and DNA-damaging agents (cis-diamminedichloroplatinum(II), etoposide, and 7-ethyl-10-hydrocycamptothecin) showed synergistic effects in six of seven cell lines but additive effects against a p53-mutated cell line. Etoposide 66-75 tumor protein p53 Homo sapiens 3-6 10930016-0 2000 Wild-type p53-dependent etoposide-induced apoptosis mediated by caspase-3 activation in human glioma cells. Etoposide 24-33 tumor protein p53 Homo sapiens 10-13 10908664-4 2000 Derangement of its transcriptional activity manifested as inhibition of p53-mediated apoptosis by etoposide, a representative antineoplastic agent. Etoposide 98-107 tumor protein p53 Homo sapiens 72-75 11070791-4 2000 Restoration of p53 protein function in LN382 cells at 34 degrees C reduced the cytotoxicity of etoposide and paclitaxel, whereas that of cisplatin and ACNU was not affected. Etoposide 95-104 tumor protein p53 Homo sapiens 15-18 11070791-6 2000 Transduction of wild-type p53 in LN382 cells also reduced the sensitivity of the cells to etoposide. Etoposide 90-99 tumor protein p53 Homo sapiens 26-29 11070791-8 2000 These results indicate that cell cycle arrest induced by wild-type p53 function may abrogate the cytotoxic effects of etoposide and paclitaxel, which are dependent on G2M-associated apoptosis. Etoposide 118-127 tumor protein p53 Homo sapiens 67-70 10913345-0 2000 Activation of the tumor metastasis suppressor gene, KAI1, by etoposide is mediated by p53 and c-Jun genes. Etoposide 61-70 tumor protein p53 Homo sapiens 86-89 10930016-8 2000 Etoposide significantly inhibited the growth of U-87MG and T-98G/p53 cells in a dose-dependent manner compared with the growth of the T-98G cells. Etoposide 0-9 tumor protein p53 Homo sapiens 65-68 10930016-9 2000 Treatment with low concentrations of etoposide resulted in the increased expression of wild-type p53; it also initiated CPP32 activity and induced apoptosis in the U-87MG cells. Etoposide 37-46 tumor protein p53 Homo sapiens 97-100 10930016-11 2000 Furthermore, low concentrations of etoposide also induced apoptosis in the T-98G/p53 cells by enhancing the expression of transfected wild-type p53, decreasing the expression of bcl-2, and activating CPP32 activity. Etoposide 35-44 tumor protein p53 Homo sapiens 81-84 10930016-11 2000 Furthermore, low concentrations of etoposide also induced apoptosis in the T-98G/p53 cells by enhancing the expression of transfected wild-type p53, decreasing the expression of bcl-2, and activating CPP32 activity. Etoposide 35-44 tumor protein p53 Homo sapiens 144-147 10930016-14 2000 CONCLUSIONS: These findings indicate that wild-type p53, CPP32, and bcl-2 may mediate apoptosis induced by etoposide. Etoposide 107-116 tumor protein p53 Homo sapiens 52-55 10930016-15 2000 Forced expression of wild-type p53 increases etoposide cytotoxicity in human glioma cells by inducing apoptosis and may have important therapeutic implications. Etoposide 45-54 tumor protein p53 Homo sapiens 31-34 10618379-5 2000 The p53 binding and transactivation of the PTGF-beta promoter was enhanced by etoposide, a p53 activator, and was largely blocked by a dominant negative p53 mutant. Etoposide 78-87 tumor protein p53 Homo sapiens 4-7 10639160-9 2000 p53-dependent cell death in the AGS human gastric cancer cell line after etoposide was similarly inhibited by transient expression of ITF but not a C-terminal truncation mutant of ITF, and it required functional phosphatidylinositol 3-kinase and EGF receptor. Etoposide 73-82 tumor protein p53 Homo sapiens 0-3 10618379-5 2000 The p53 binding and transactivation of the PTGF-beta promoter was enhanced by etoposide, a p53 activator, and was largely blocked by a dominant negative p53 mutant. Etoposide 78-87 tumor protein p53 Homo sapiens 91-94 10618379-5 2000 The p53 binding and transactivation of the PTGF-beta promoter was enhanced by etoposide, a p53 activator, and was largely blocked by a dominant negative p53 mutant. Etoposide 78-87 tumor protein p53 Homo sapiens 91-94 10618379-6 2000 Furthermore, expression of endogenous PTGF-beta was remarkably induced by etoposide in p53-positive, but not in p53-negative, cell lines. Etoposide 74-83 tumor protein p53 Homo sapiens 87-90 10505853-7 1999 Analysis of cell cycle and apoptosis in etoposide-treated cells corroborated the inability of NP-29 to die by apoptosis, suggesting that this wt p53 cell line lacks p53 downstream functions in the apoptosis pathway. Etoposide 40-49 tumor protein p53 Homo sapiens 145-148 10722231-4 2000 Interestingly, lymphoma cells were still sensitive to p53-mediated apoptosis induced by etoposide. Etoposide 88-97 tumor protein p53 Homo sapiens 54-57 10544021-3 1999 In the present study, we showed that the topoisomerase II inhibitor of widely used anticancer drugs etoposide and doxorubicin activated wt p53 in BL2, a Burkitt"s lymphoma cell line which overexpressed MDM2. Etoposide 100-109 tumor protein p53 Homo sapiens 139-142 10544021-8 1999 This p53 was co-immunoprecipitated with MDM2, but p53 activated by etoposide or doxorubicin barely complexed with MDM2. Etoposide 67-76 tumor protein p53 Homo sapiens 5-8 10544021-8 1999 This p53 was co-immunoprecipitated with MDM2, but p53 activated by etoposide or doxorubicin barely complexed with MDM2. Etoposide 67-76 tumor protein p53 Homo sapiens 50-53 10769650-4 2000 Induction of p53-dependent apoptosis was observed in the etoposide treatment group, the X-ray irradiation group, and the combined (etoposide + X-ray irradiation) group. Etoposide 57-66 tumor protein p53 Homo sapiens 13-16 10769650-4 2000 Induction of p53-dependent apoptosis was observed in the etoposide treatment group, the X-ray irradiation group, and the combined (etoposide + X-ray irradiation) group. Etoposide 131-140 tumor protein p53 Homo sapiens 13-16 10644891-7 2000 The representative cell line NCI-H1437 cells transfected with wild-type p53 gene (H1437/wtp53) showed a dramatic increase in susceptibility to three anticancer agents (7-fold to cisplatin, 21-fold to etoposide, and 20-fold to camptothecin) compared to untransfected or neotransfected H1437 cells. Etoposide 200-209 tumor protein p53 Homo sapiens 72-75 10502297-2 1999 The stable expression of wild-type p53 resulted in a significant increase in sensitivity to the topoisomerase II poisons etoposide and doxorubicin, but not to the topoisomerase II inhibitors razoxane and ADR-529. Etoposide 121-130 tumor protein p53 Homo sapiens 35-38 10207030-8 1999 Etoposide-induced transactivation was blocked by a dominant negative p53 mutant, indicating that endogenous wild type p53, upon activation by etoposide, transactivated the GPX promoter. Etoposide 0-9 tumor protein p53 Homo sapiens 118-121 10206959-18 1999 The down-regulation of hMMP-1 gene expression by endogenous wt-p53 was shown by treatment of U2-OS cells, a wt-p53-containing osteogenic sarcoma line, and Saos-2 cells, a p53-negative osteogenic sarcoma line, with etoposide, a potent inducer of p53 expression. Etoposide 214-223 tumor protein p53 Homo sapiens 63-66 10206959-19 1999 p53, activated by etoposide, appears to block hMMP-1 promoter activity induced by etoposide in U2-OS cells. Etoposide 18-27 tumor protein p53 Homo sapiens 0-3 10206959-19 1999 p53, activated by etoposide, appears to block hMMP-1 promoter activity induced by etoposide in U2-OS cells. Etoposide 82-91 tumor protein p53 Homo sapiens 0-3 10402229-3 1999 A lower level of p53 was induced in CDK inhibitor-expressing etoposide-exposed cells suggesting that protection may be due to lower levels of DNA damage in the growth arrested cells. Etoposide 61-70 tumor protein p53 Homo sapiens 17-20 10339661-4 1999 However, the sensitivity to radiation was significantly improved by the transduction and T.Tn/p53 cells became markedly susceptible to cisplatin and etoposide compared with parental cells. Etoposide 149-158 tumor protein p53 Homo sapiens 94-97 10207030-4 1999 This site bound to purified p53 as well as p53 in nuclear extract activated by etoposide. Etoposide 79-88 tumor protein p53 Homo sapiens 28-31 10207030-4 1999 This site bound to purified p53 as well as p53 in nuclear extract activated by etoposide. Etoposide 79-88 tumor protein p53 Homo sapiens 43-46 10207030-8 1999 Etoposide-induced transactivation was blocked by a dominant negative p53 mutant, indicating that endogenous wild type p53, upon activation by etoposide, transactivated the GPX promoter. Etoposide 142-151 tumor protein p53 Homo sapiens 69-72 10207030-7 1999 The p53 binding and transactivation of the GPX promoter were enhanced by etoposide in p53-positive U2-OS cells. Etoposide 73-82 tumor protein p53 Homo sapiens 4-7 10207030-7 1999 The p53 binding and transactivation of the GPX promoter were enhanced by etoposide in p53-positive U2-OS cells. Etoposide 73-82 tumor protein p53 Homo sapiens 86-89 10207030-8 1999 Etoposide-induced transactivation was blocked by a dominant negative p53 mutant, indicating that endogenous wild type p53, upon activation by etoposide, transactivated the GPX promoter. Etoposide 142-151 tumor protein p53 Homo sapiens 118-121 10207030-8 1999 Etoposide-induced transactivation was blocked by a dominant negative p53 mutant, indicating that endogenous wild type p53, upon activation by etoposide, transactivated the GPX promoter. Etoposide 0-9 tumor protein p53 Homo sapiens 69-72 10094469-1 1999 S100A2, a calcium binding protein of the EF-hand family, was recently identified to be inducible by etoposide, a p53 activator. Etoposide 100-109 tumor protein p53 Homo sapiens 113-116 10082308-3 1999 METHODS: We report here a parallel flow cytometric method for semiquantitative detection of p53 protein and apoptosis (percent of apoptotic cells) in a pre-B leukemic cell line (NALM-6) exposed to various antitumor agents (2.35 microg/ml etoposide; 0.175 microg/ml FCE296; 0.4 microg/ml FCE624; and 1.5 microg/ml L-PAM). Etoposide 238-247 tumor protein p53 Homo sapiens 92-95 10094469-5 1999 Furthermore, endogenous S100A2 mRNA expression is induced by etoposide in p53 positive, but not in p53 negative cells. Etoposide 61-70 tumor protein p53 Homo sapiens 74-77 10094470-1 1999 DNA chip technology was used in an attempt to identify target genes responsible for apoptosis induced by etoposide, a p53 activating topoisomerase II inhibitor used clinically as an antitumor agent. Etoposide 105-114 tumor protein p53 Homo sapiens 118-121 10094469-2 1999 A potential p53 binding site was identified in the promoter of the S100A2 gene, which binds to purified p53 as well as p53 in nuclear extract activated by etoposide. Etoposide 155-164 tumor protein p53 Homo sapiens 12-15 10094469-2 1999 A potential p53 binding site was identified in the promoter of the S100A2 gene, which binds to purified p53 as well as p53 in nuclear extract activated by etoposide. Etoposide 155-164 tumor protein p53 Homo sapiens 104-107 10094469-2 1999 A potential p53 binding site was identified in the promoter of the S100A2 gene, which binds to purified p53 as well as p53 in nuclear extract activated by etoposide. Etoposide 155-164 tumor protein p53 Homo sapiens 104-107 10094469-4 1999 The p53-induced transactivation of the S100A2 promoter was enhanced by etoposide and blocked by a dominant negative p53 mutant. Etoposide 71-80 tumor protein p53 Homo sapiens 4-7 9927204-5 1999 Clonogenic survival assays revealed that cells overexpressing the p53His175 mutant, but not the p53His273 mutant, recover preferentially from etoposide treatment. Etoposide 142-151 tumor protein p53 Homo sapiens 66-69 10023685-0 1999 Differential regulation of p21waf-1/cip-1 and Mdm2 by etoposide: etoposide inhibits the p53-Mdm2 autoregulatory feedback loop. Etoposide 54-63 tumor protein p53 Homo sapiens 88-91 10023685-0 1999 Differential regulation of p21waf-1/cip-1 and Mdm2 by etoposide: etoposide inhibits the p53-Mdm2 autoregulatory feedback loop. Etoposide 65-74 tumor protein p53 Homo sapiens 88-91 10023685-9 1999 When cells are -treated with a pulse (1 h) of etoposide and reincubated in drug free medium, Mdm2 synthesis commences immediately after damage is repaired (3 h) and the p53 response is attenuated. Etoposide 46-55 tumor protein p53 Homo sapiens 169-172 9927204-6 1999 Moreover, p53His175 as well as p53His179 reduced substantially the rate of etoposide-induced apoptosis, whereas p53His273 and p53Trp248 had a much milder protective effect. Etoposide 75-84 tumor protein p53 Homo sapiens 31-34 9927204-6 1999 Moreover, p53His175 as well as p53His179 reduced substantially the rate of etoposide-induced apoptosis, whereas p53His273 and p53Trp248 had a much milder protective effect. Etoposide 75-84 tumor protein p53 Homo sapiens 10-13 14646555-4 1997 p53 and p21/waf1 protein levels were elevated in etoposide-treated cells, but not in cells subjected to serum with-drawal. Etoposide 49-58 tumor protein p53 Homo sapiens 0-3 9772293-4 1998 With the exception of the etoposide-effected G2/M arrest at high concentrations, which seems to depend on functional p53, since it did not occur in cells with inactive p53. Etoposide 26-35 tumor protein p53 Homo sapiens 117-120 9772293-7 1998 The accumulated p53 was biochemically active, as measured in a transient transfection assay upon treatment with gemcitabine, cisplatin, etoposide, and Taxol. Etoposide 136-145 tumor protein p53 Homo sapiens 16-19 9788435-3 1998 The effect of induced p53 and p21waf1 expression on the cytotoxic action of the anti-cancer drugs etoposide and cisplatin was also analysed. Etoposide 98-107 tumor protein p53 Homo sapiens 22-25 9660477-9 1998 Camptothecin and etoposide increased the p53 level after 4 hours of treatment, before the onset of apoptosis. Etoposide 17-26 tumor protein p53 Homo sapiens 41-44 9343394-6 1997 Treatment of U2-OS cells, a wild-type p53-containing osteogenic sarcoma line, with a common p53 inducer, etoposide, induced p53 DNA binding and transactivation activities in a time-dependent manner. Etoposide 105-114 tumor protein p53 Homo sapiens 38-41 9343394-6 1997 Treatment of U2-OS cells, a wild-type p53-containing osteogenic sarcoma line, with a common p53 inducer, etoposide, induced p53 DNA binding and transactivation activities in a time-dependent manner. Etoposide 105-114 tumor protein p53 Homo sapiens 92-95 9343394-6 1997 Treatment of U2-OS cells, a wild-type p53-containing osteogenic sarcoma line, with a common p53 inducer, etoposide, induced p53 DNA binding and transactivation activities in a time-dependent manner. Etoposide 105-114 tumor protein p53 Homo sapiens 92-95 9923540-10 1999 Our observations support the concept that cells carrying the wild-type p53 gene tend to be sensitive to etoposide and DXR and, in particular, deletion of the p53 function results in a greater resistance to anticancer agents. Etoposide 104-113 tumor protein p53 Homo sapiens 71-74 9923540-10 1999 Our observations support the concept that cells carrying the wild-type p53 gene tend to be sensitive to etoposide and DXR and, in particular, deletion of the p53 function results in a greater resistance to anticancer agents. Etoposide 104-113 tumor protein p53 Homo sapiens 158-161 9687575-8 1998 Importantly, we could show that MT1 cells are not deficient in the p53-dependent apoptosis pathway; treatment with etoposide, a topoisomerase II inhibitor, resulted in p53 and p21/waf-1 protein expression and apoptosis in both cell lines. Etoposide 115-124 tumor protein p53 Homo sapiens 168-171 9506540-3 1998 When p53 was expressed at sublethal levels, it sensitized cells to the DNA-damaging drugs Adriamycin, mitomycin C, actinomycin D, etoposide (VP16), cisplatin and CPT11. Etoposide 130-139 tumor protein p53 Homo sapiens 5-8 9506540-3 1998 When p53 was expressed at sublethal levels, it sensitized cells to the DNA-damaging drugs Adriamycin, mitomycin C, actinomycin D, etoposide (VP16), cisplatin and CPT11. Etoposide 141-145 tumor protein p53 Homo sapiens 5-8 9494534-8 1997 Levels of p53 mRNA decreased with increasing resistance to vindesine, etoposide and fotemustine. Etoposide 70-79 tumor protein p53 Homo sapiens 10-13 8950479-5 1996 In vitro studies with a bladder carcinoma cell line containing a wild type p53 showed that it underwent a G1 checkpoint after etoposide, potentially allowing DNA damage repair, as well as apoptosis. Etoposide 126-135 tumor protein p53 Homo sapiens 75-78 8875976-7 1996 Moreover, when the DNA damage-inducing drugs etoposide or camptothecin were added to the cells, a further stimulation of kinase activity was observed following growth at 28 degrees C, but not 38 degrees C. These data are consistent with a regulatory model in which p53 is sensitive to stress or DNA damage through phosphorylation at its N-terminus. Etoposide 45-54 tumor protein p53 Homo sapiens 265-268 8706243-3 1996 Sublines that were resistant to melphalan, pyrazafurin, mitoxantrone, etoposide and PALA all retained expression of wild-type p53. Etoposide 70-79 tumor protein p53 Homo sapiens 126-129 8620501-0 1996 Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax:Bcl-2 ratio. Etoposide 47-56 tumor protein p53 Homo sapiens 105-108 8673929-4 1996 In vitro investigations have shown intact p53 to play a critical role executing cell death in response to treatment with cytotoxic drugs like 5-fluorouracil, etoposide and doxorubicin. Etoposide 158-167 tumor protein p53 Homo sapiens 42-45 8620501-8 1996 First, they have functional p53: the product of the p53-dependent gene waf-1 was increased after etoposide treatment. Etoposide 97-106 tumor protein p53 Homo sapiens 28-31 8620501-8 1996 First, they have functional p53: the product of the p53-dependent gene waf-1 was increased after etoposide treatment. Etoposide 97-106 tumor protein p53 Homo sapiens 52-55 7750085-1 1995 Anticancer drugs etoposide and mitomycin C increased nuclear p53 protein and decreased proliferating cell nuclear antigen (PCNA) of PLC/PRF/5 human hepatoma cells. Etoposide 17-26 tumor protein p53 Homo sapiens 61-64 8562479-5 1995 HL60 cells transfected with wild-type p53 were more sensitive to stress, such as growth in serum-depleted medium and exposure to a chemotherapeutic agent, etoposide. Etoposide 155-164 tumor protein p53 Homo sapiens 38-41 9815936-0 1995 Expression of topoisomerase II, bcl-2, and p53 in three human brain tumor cell lines and their possible relationship to intrinsic resistance to etoposide. Etoposide 144-153 tumor protein p53 Homo sapiens 43-46 9816212-8 1996 Targeted loss of p53 protein in H460 lung cancer cells using HPV-16 E6 inhibited the etoposide-induced G1 checkpoint but did not decrease chemosensitivity. Etoposide 85-94 tumor protein p53 Homo sapiens 17-20 7970699-4 1994 The DNA damaging agent etoposide induced p53 accumulation only in cells harboring wild-type p53 yet it induced WAF1/Cip1 gene expression in cells carrying wild-type or mutant p53, suggesting the involvement of p53-dependent and independent signaling pathways in the regulation of WAF1/Cip1 gene expression. Etoposide 23-32 tumor protein p53 Homo sapiens 41-44 7970699-4 1994 The DNA damaging agent etoposide induced p53 accumulation only in cells harboring wild-type p53 yet it induced WAF1/Cip1 gene expression in cells carrying wild-type or mutant p53, suggesting the involvement of p53-dependent and independent signaling pathways in the regulation of WAF1/Cip1 gene expression. Etoposide 23-32 tumor protein p53 Homo sapiens 92-95 7970699-4 1994 The DNA damaging agent etoposide induced p53 accumulation only in cells harboring wild-type p53 yet it induced WAF1/Cip1 gene expression in cells carrying wild-type or mutant p53, suggesting the involvement of p53-dependent and independent signaling pathways in the regulation of WAF1/Cip1 gene expression. Etoposide 23-32 tumor protein p53 Homo sapiens 92-95 7970699-4 1994 The DNA damaging agent etoposide induced p53 accumulation only in cells harboring wild-type p53 yet it induced WAF1/Cip1 gene expression in cells carrying wild-type or mutant p53, suggesting the involvement of p53-dependent and independent signaling pathways in the regulation of WAF1/Cip1 gene expression. Etoposide 23-32 tumor protein p53 Homo sapiens 92-95 8485705-2 1993 Activation of p53-DNA binding was seen for treatment with radiation, hydrogen peroxide, actinomycin D, Adriamycin, etoposide, camptothecin, 5-fluorouracil, mitomycin C, and cisplatin. Etoposide 115-124 tumor protein p53 Homo sapiens 14-17 7954409-1 1994 The present study assessed the role of the p53 tumor suppressor gene in cell cycle arrest and apoptosis following treatment of Burkitt"s lymphoma and lymphoblastoid cell lines with gamma-rays, etoposide, nitrogen mustard, and cisplatin. Etoposide 193-202 tumor protein p53 Homo sapiens 43-46 7954409-3 1994 We found that gamma-rays and etoposide induced a strong G1 arrest in the wild-type p53 lines while nitrogen mustard and cisplatin induced relatively little G1 arrest. Etoposide 29-38 tumor protein p53 Homo sapiens 83-86 7954409-5 1994 The degree of G1 arrest observed with these agents correlated with the rate of p53 and p21Waf1/Cip1 protein accumulation: gamma-rays and etoposide induced rapid accumulation of both p53 and p21Waf1/Cip1; nitrogen mustard and cisplatin induced slow accumulation of p53 and no major accumulation of the p21Waf1/Cip1 protein. Etoposide 137-146 tumor protein p53 Homo sapiens 79-82 7954409-5 1994 The degree of G1 arrest observed with these agents correlated with the rate of p53 and p21Waf1/Cip1 protein accumulation: gamma-rays and etoposide induced rapid accumulation of both p53 and p21Waf1/Cip1; nitrogen mustard and cisplatin induced slow accumulation of p53 and no major accumulation of the p21Waf1/Cip1 protein. Etoposide 137-146 tumor protein p53 Homo sapiens 182-185 7954409-5 1994 The degree of G1 arrest observed with these agents correlated with the rate of p53 and p21Waf1/Cip1 protein accumulation: gamma-rays and etoposide induced rapid accumulation of both p53 and p21Waf1/Cip1; nitrogen mustard and cisplatin induced slow accumulation of p53 and no major accumulation of the p21Waf1/Cip1 protein. Etoposide 137-146 tumor protein p53 Homo sapiens 182-185 7954409-8 1994 We also observed an inverse sensitivity relationship between nitrogen mustard/cisplatin and etoposide in the mutant p53 lines and this was found to correlate with topoisomerase II mRNA levels in the cells. Etoposide 92-101 tumor protein p53 Homo sapiens 116-119 7923116-4 1994 Induction of p53 is also abnormal in AT cells following treatment with methylmethanesulfonate and bleomycin but appears relatively normal following treatment with UV-C irradiation or the topoisomerase inhibitors, etoposide and camptothecin. Etoposide 213-222 tumor protein p53 Homo sapiens 13-16 35421634-3 2022 Doxorubicin and etoposide were used to induce cell senescence as determined by the cessation of cell proliferation, augmented senescence-associated beta-galactosidase (SA-beta-Gal) staining, and increased p53 expression levels. Etoposide 16-25 tumor protein p53 Homo sapiens 205-208 35178190-0 2022 Etoposide-induced DNA damage is increased in p53 mutants: identification of ATR and other genes that influence effects of p53 mutations on Top2-induced cytotoxicity. Etoposide 0-9 tumor protein p53 Homo sapiens 45-48 35178190-4 2022 We assessed the impact of the loss of p53 function on the formation of DNA damage induced by the Top2 poison etoposide. Etoposide 109-118 tumor protein p53 Homo sapiens 38-41 35178190-5 2022 Using human HCT116 cells, we found resistance to etoposide in cell growth assays upon the functional loss of p53. Etoposide 49-58 tumor protein p53 Homo sapiens 109-112 35178190-6 2022 Nonetheless, cells lacking fully functional p53 were etoposide hypersensitive in clonogenic survival assays. Etoposide 53-62 tumor protein p53 Homo sapiens 44-47 35178190-9 2022 Employing genome-wide siRNA screens, we identified a set of genes for which reduced expression resulted in enhanced synthetic lethality upon etoposide treatment of p53 defective cells. Etoposide 141-150 tumor protein p53 Homo sapiens 164-167 35178190-10 2022 We focused on one hit from this screen, ATR, and showed that decreased expression sensitized the p53-defective cells to etoposide in all assays and generated elevated levels of Top2cc in both p53 proficient and deficient cells. Etoposide 120-129 tumor protein p53 Homo sapiens 97-100 34411980-11 2021 Combination studies revealed that both compounds had synergistic effects (combination index CI < 1) on Cis and Eto through induction of apoptosis (p53 activation and up-regulation of BAX and p21 gene expression). Etoposide 111-114 tumor protein p53 Homo sapiens 147-150 35410287-4 2022 RESULTS: By combining single-cell imaging and mathematical modeling of dose-dependent p53 dynamics induced by three chemotherapeutics of distinct mechanism-of-actions, including Etoposide, Nutlin-3a and 5-fluorouracil, and in five cancer cell types, we uncovered novel and highly variable p53 dynamic responses, in particular p53 transitional dynamics induced at intermediate drug concentrations, and identified the functional roles of distinct positive and negative feedback motifs of the p53 pathway in modulating the central p53-Mdm2 negative feedback to generate stimulus- and cell type-specific signaling responses. Etoposide 178-187 tumor protein p53 Homo sapiens 86-89 35217496-9 2022 CONCLUSIONS: Taken together, we show that DLG2 over expression increases p53 mediated apoptosis in response to etoposide and UVC mediated genotoxicity and reduced DNA replication machinery. Etoposide 111-120 tumor protein p53 Homo sapiens 73-76